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The Central/South American population is growing rapidly in the U.S., but little is 
known about the health status.  The purpose of this study was 1) to estimate the 
prevalence of MS and its individual components, 2) compare risk factors among 
Hispanic sub-groups, and 3) examine how metabolic syndrome (MS) prevalence 
estimates have changed from 1993-1994 to 2008-2009 in a sample of Central/South 
Americans living in the D.C. area.  In this cross-sectional, medical record xtraction 
survey, data from 1993-1994 were compared with data from 2008-2009 on 1,042 
male and female adults collected by questionnaire.  28% of our subjects had MS.  The 
most prevalent MS components were low HDL (43.2% men; 50.7% women), 
elevated triglycerides (37%), and high BMI ≥ 25 kg/m2 (75.6%).  Among 
Central/South Americans, Salvadorans had the highest prevalence of MS (30.7%).  
  
MS prevalence was significantly greater for the 2008-2009 subjects (27.9%) 
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Chapter 1: Introduction 
 
Cardiovascular diseases (CVD) are among the nation’s leading causes of death. 
CVD is defined as diseases of the heart and blood vessels. CVD encompasses 
cerebrovascular disease (stroke), raised blood pressure, peripheral artery disease, heart 
failure, and the most common, coronary heart disease (CHD) (Rosamond et al., 2008).  
CHD is the leading cause of death in the United States (U.S.), causing approximately 
53% of all deaths annually (Rosamond et al., 2008).  The causes of CHD are multi-
factorial and occur in a multi-step process. Underlying risk factors (obesity, physical 
inactivity, and atherogenic diet) give rise to major atherogenic risk factors (cigarette 
smoking, hypertension, elevated low-density lipoprotein (LDL) cholesterol, and agi g), 
which then leads to the formation of coronary atherosclerosis. Coronary atherosclerosi  is 
essentially the pathological process leading to CHD; it is caused by elevated levels (≥ 100 
mg/dL) of LDL cholesterol (Grundy et al., 2001). CHD is highly prevalent amongst 
Americans primarily due to the strong relationship that CHD has with dietary int ke. Diet 
affects the risk factors for CHD and many other chronic diseases, including Diabetes 
Mellitus (DM), strokes, and certain cancers (Martínez-Ortiz, Fung, Baylin, Hu, & H 
Campos, 2006); all of which are among the top ten leading causes of death in the U.S.  
Metabolic Syndrome (MS) is a cluster of metabolic abnormalities that occur
together in an individual and are associated with an increased risk of developing 
cardiovascular disease (CVD) and type 2 DM (Meigs et al., 2003). The first 
acknowledgment of this syndrome that was documented was in 1988 by Gerald Reaven, 
when he coined the term “syndrome X.” At that time, Reaven considered the following 
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abnormalities to be characteristic of syndrome X: resistance to insulin-stimulated glucose 
uptake, glucose intolerance, hyperinsulinemia, increased triglycerides, decreased high-
density lipoprotein (HDL) cholesterol, and hypertension (Ford & Giles, 2003). Now 
known as the metabolic syndrome, other abnormalities have been associated with the 
syndrome, including central obesity, proinflammatory state, and prothrombotic state, all 
of which increase the risk of developing CVD and DM. MS is closely associated with a 
generalized metabolic disorder called insulin resistance, i  which tissue responsiveness to 
the normal action of insulin is impaired (National Cholesterol Education Program Adult 
Treatment Panel III [NCEP ATP III], 2002). Overweight/obesity, physical inactivity, and 
genetic factors are the underlying causes of the MS.  
Each of these MS components alone has detrimental health effects, but when 
combined, the components become more “powerful” (Reaven, 2006) by increasing the 
likelihood of developing CVD. Each definition of MS possesses, but is not limited to, the 
aforementioned components. The criteria and/or cutoff values of MS definitions may 
vary slightly. The definition of the MS has evolved over time. However, there are five 
commonly accepted components which are agreed upon by several organizations, such as 
the NCEP, International Diabetes Federation (IDF), European Group for the Study of 
Insulin Resistance (EGIR), and the World Health Organization (WHO). 
Much of the known information about chronic diseases in the U.S. has been 
generated by large national studies such as the National Health and Nutrition 
Examination Survey (NHANES).  NHANES is conducted to ascertain the current health
and nutrition status of non-Hispanic whites, non-Hispanic blacks, and Hispanic 
Americans of Mexican, Puerto Rican, and Cuban descent living in the U.S. Despite the 
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wealth of information on these established Hispanic Americans, generalizations should 
not be made to other Hispanic subgroups. According to Nath (2005), “Findings from one 
Hispanic subgroup cannot be applicable or extrapolative to other Hispanic subgroups 
because each subgroup's social histories, cultural identities, health behaviors, and genetic 
compositions are unique.”  
Despite the significant awareness of risk factors for CHD in these commonly 
studied groups of Americans, very little is known about the prevalence of MS among 
Central and South Americans. Central Americans, specifically, are the fasest growing 
group of Hispanics in the U.S., followed by South Americans. The most recent statistic  
from the U.S. Census estimate that there are 44.3 million Hispanic Americans, with 
13.1% (5,793,387) originating from Central and South America (U.S. Census Bureau, 
2006). Mexican-Americans make up 64% of the total Hispanic population. The total 
Hispanic population is 14.8% of the total U.S. population of 299 million (U.S. Census 
Bureau, 2006). These estimates are not inclusive of all Hispanics living in the U.S., they 
do not include all unauthorized immigrants. The population of all unauthorized 
immigrants is estimated to be approximately 11.9 million, 4% of the nation’s population, 
as of 2008 (Passel & Cohn, 2009). The Hispanic population is the fastest growing and 
largest minority group in the U.S. It is projected that this group will reach 59.7 million by 
the year 2020 (U.S. Census Bureau, 2006).  
 NCEP has established their third expert panel on detection, evaluation, and 
treatment of high blood cholesterol in adults (ATP III). This panel of medical and public 
health experts convened to make recommendations for updating the ATP II guidelines for 
cholesterol testing and management. Recommendations were made based on research 
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studies and the newest cholesterol-lowering medications, and considering the obesity 
epidemic and increasing rates of CHD mortality in the U.S. The increasing rates of CHD 
may be associated with the incidence of MS (NCEP ATP III, 2002).   
In research studies conducted to determine the prevalence and/or risk for CHD 
prior to the development of the ATP III MS criteria, CHD risks were based on ATP II 
criteria. The recommendations of ATP II varied slightly from that of the current, updated 
recommendations of ATP III. The amendments to the recommendations were made by 
the expert panel based on controlled clinical trials that tested the newest cholesterol-
lowering drugs (NCEP ATP III, 2002). ATP III offers an integrated set of new 
recommendations and guidelines, although many of its features remained the same. Some 
features of the report of the ATP have gone unchanged since the first panel, ATP I. 
Despite the similar features, each updated report has a new thrust. ATP I had major 
interests and strategies for primary prevention of CHD in those with elevatd LDL 
cholesterol (≥160 mg/dL) or those with borderline levels of LDL cholesterol (130-159 
mg/dL) plus multiple (2 or more) other risk factors. ATP II proclaimed the importance of 
the approach taken by ATP I, and then added a new feature. They added an intensive 
LDL management component for persons with diagnosed CHD. ATP II also set a new 
lower LDL cholesterol threshold of ≤100 mg/dL for CHD patients. ATP III, like ATP II, 
maintained the original approach of primary prevention of CHD and intensive 
management of LDL, while implementing a major new feature: primary prevention i  
persons with multiple risk factors. The significance of the new feature was that it proved 
more beneficial for those with multiple risk factors to receive even more intense LDL 
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management (more than what is recommended in ATP II) due to the high risk for CHD 
(NCEP ATP III, 2002).          
There are several shared features of ATP III and ATP II. The ATP III report states 
that these features are: Continued identification of LDL cholesterol lowering as the 
primary goal of therapy; Consideration of high LDL cholesterol (≥160 mg/dL) as a 
potential target for LDL-lowering drug therapy, specifically for persons who continue to 
maintain high LDL levels (with or without multiple risk factors) even after di tary 
therapy; Emphasis on intensive LDL-lowering therapy in persons with established CHD; 
Identification of three categories of risk for different LDL goals and different intensities 
of LDL-lowering therapy, for those with CHD, multiple (2+) risk factors, and 0-1 risk 
factor; Identification of population groups, besides middle-aged men, for detection of 
high LDL cholesterol and for clinical intervention, specifically young adults, 
postmenopausal women, and older persons; and Emphasis on weight loss and physical 
activity to enhance risk reduction in persons with elevated LDL cholesterol (NCEP ATP 
III, 2002).  
The new features of ATP III focus on multiple risk factors with modifications of 
lipid and lipoprotein classification, and show support for implementation. A person with 
diabetes, but not CHD is raised to the risk level of CHD risk equivalent, due to the 
likelihood of multiple risk factors. The low HDL cholesterol threshold was raised from 
<35 mg/dL to <40 mg/dL for better indication of depressed HDL; while the optimal LDL 
cholesterol level was identified as <100 mg/dL. A recommendation was made to analyze 
total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides as an initial 
screening, as opposed to total or HDL cholesterol alone. Strategies were presented for 
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promoting adherence to drug therapies, as well as therapeutic lifestyle changes (NCEP 
ATP III, 2002).  
     One major difference between ATP II and ATP III is the establishment of the 
definition of MS. The MS definition was developed and drew attention to its importance 
as a CHD risk factor and consequently included in ATP III, which provided a working 
definition of the syndrome for the first time (Ford & Giles, 2003). ATP II had set crit ria 
for identifying CHD risk based on serum LDL cholesterol levels. The three risk 
categories were: borderline high LDL cholesterol (130-150 mg/dL) with fewer than two 
major risk factors, borderline high LDL cholesterol (130-150 mg/dL) with two or more 
major risk factors, and high LDL cholesterol (≥160 mg/dL). ATP III not only uses LDL 
cholesterol, but other risk factors to determine the presence of the MS, which ultimately 
leads to CHD.  
In this study, modified NCEP ATP III criteria will be used to identify the MS
among a Central and South American sample. In a similar study, (Miner & Jackson, 
1995) used the ATP II criteria for identifying Central and South Americans who were at 
risk of developing CHD. MS criteria had not yet been established at the time of th  study; 
however, more recent studies use MS definitions to identify those same risks. The most 
commonly used MS definition in the U.S. is that of NCEP ATP III. MS is diagnosed if an 
individual has any combination of three or more of the following risk factors: abdominal 
obesity, as measured by waist circumference, >102 cm and >88 cm for men and women, 
respectively; triglycerides ≥150 mg/dL; HDL cholesterol <40 mg/dL and <50 mg/dL for 
men and women, respectively; blood pressure ≥130/85 mmHg; and fasting blood glucose 
≥110 mg/dL (NCEP ATP III, 2002). Subjects will be stratified among the Body Mass 
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Index (BMI) categories normal weight, overweight, and obesity to determin  if the MS is 
more prevalent at a higher relative weight.  
Central and South Americans are understudied in the U.S.; therefore, very little 
information is available on the health status of this population. This study provides data 
on the prevalence of MS in this population. It will elucidate differences in risk factors 
that may or may not exist between Hispanic subgroups. This research will be useful for 
public health planning, education, as well as program implementation that can offer 





1. What is the prevalence of abnormal MS indicators (FPG, TG, HDL, HBP, BMI) in 
a sample of Hispanics utilizing the Spanish Catholic Center? 
2. Are there differences in the prevalence of MS among various Hispanic sub-groups, 
such as Salvadorans, Hondurans, and Guatemalans? 
3. Is there a difference in the prevalence of abnormal MS indicators based on BMI 
categories? 
4. How does the prevalence of MS and abnormal MS indicators in this population 




Chapter 2: Literature Review 
Central and South America consists of 21 countries with an estimated population 
of over 420 million people (Central Intelligence Agency [CIA], 2009). Despite being 
grouped as one type of people, Latin Americans are very diverse with various racial and 
cultural backgrounds. There are approximately 500-750 languages spoken in Central and 
South America today (Campbell, 1997). As of 2006, the number of people living in 
poverty in Latin America was approximately 205 million (38.5%). Poverty, as defined by 
the Pan American Health Organization (PAHO), is as follows:  “A person is clas ified as 
“poor” when the per capita income of the household in which he or she lives falls below 
the “poverty line”—or the minimum income the members of a household must have in 
order to meet the basic needs (Pan American Health Organization [PAHO], 2007). “The 
poverty rates have been on the decline since 2002, when the rate was 221 million (44.0%) 
(PAHO, 2007). The poverty rate in some countries is very high, whereas in other 
countries the rate is very low. Poverty rates have been determined for the following 
countries based on the most recent available estimates (from highest to lowest):  
Honduras (74.8%), Nicaragua (69.3%), Bolivia (63.9%), Paraguay (60.5%), Peru 
(51.1%), Ecuador (48.3%), Dominican Republic (47.5%), Colombia (46.8%), Guatemala 
(45.3%), El Salvador (41.2%), Venezuela (37.1%), Brazil (36.3%), Panama (33.0%), 
Argentina (26.0%), Costa Rica (21.1%), Uruguay (18.8%), and Chile (18.7%). The 
poverty rate for Mexico is 35.5% (PAHO, 2007). The PAHO, (2007) states that “the 
poverty rate is almost twice as high in rural areas as in urban ones and the indigence rat  
is almost triple.” The PAHO defines indigence as:  “A person is classified as “indigent” 
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when the per capita income of the household in which he or she lives is below the 
“indigence line” or below the minimum income the members of a household must have in 
order to purchase the cost of a basic food basket, taking into consideration consumption 
habits, the effective availability of foodstuffs and their relative prices, as well as the 
differences between metropolitan areas, other urban areas, and rural areas” (PAHO, 
2007).  
The PAHO estimates that the leading causes of death in Latin America are from 
cardiovascular diseases and diabetes mellitus (PAHO, 2007).  Mortality rates for 
cardiovascular diseases were highest in Nicaragua (219.4) and Dominican Republic 
(237.5), far exceeding 200 per 100,000 people. Countries such as Paraguay, Brazil, 
Colombia, Venezuela, Argentina, and Uruguay had mortality rates from that cause 
greater than 150, but below 200, per 100,000 people. The countries with the lowest 
mortality (less than 150 per 100,000) from cardiovascular diseases are Panama, El 
Salvador, Mexico, Costa Rica, Puerto Rico, Chile, Ecuador, and Peru (PAHO, 2007). 
Between the years of 1970 and 2000, mortality rates have varied among different 
countries. Mortality from ischemic heart disease increased in Costa Rica, Ecuador, 
Mexico, and Venezuela during that period due to unfavorable changes with respect to 
diet, obesity, smoking, and lack of physical activity, while a sharp decline was seen only 
in Argentina. Mortality from cerebrovascular diseases (stroke) dropped anywhere from 
10% to 49% in the majority of Latin American countries, except for Venezuela, whose 
rate remained unchanged. It is worth noting that the mortality rate from stke  dropped 
60% in the U.S. between the same years. The difference between rates is most likely due 
to, although the reasons are not well known, significant differences in education and 
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access to services, quality of medical care, the incidence of cerebrovascular events, and 
risk-factor control (PAHO, 2007). 
  Hypertension, a major risk factor for heart disease and stroke, was found to be 
highest in Chile (38.3%), followed by Costa Rica and Nicaragua with rates between 25% 
and 34%. El Salvador, Guatemala, and Honduras had prevalence rates lower than 25% 
(PAHO, 2007). Hypercholesterolemia, another major and independent risk factor for 
heart disease and stroke, affects millions of people around the world. Research conducted 
in 2003-2004 by the Central American Diabetes Initiative showed that the prevalence for 
hypercholesterolemia in Nicaragua was 19.7%, 45.7% in Costa Rica, and 35.5% in 
Guatemala (PAHO, 2007). According to the 2005 National Survey of Risk Factors in 
Argentina, 27.8% of participants self-reported having high levels of cholesterol (PAHO, 
2007). The 2003 Health Survey in Chile found the prevalence of high total cholesterol to 
be 25% (PAHO, 2007).  
The PAHO stated that “diabetes mellitus represents a major public health problem 
in the Americas, and there is evidence that its prevalence is increasing in ome countries 
(Barceló & Rajpathak, 2001).” DM was the fourth leading cause of death in Latin 
America in 2001, with 5% of all deaths. However, it was the leading cause of death in 
Mexico in 2002 (12.8%), representing the first and second cause of death for women and 
men, respectively. There was an estimated 13.3 million people with DM in Latin America 
in 2000. By the year 2030, the population with DM is expected to reach 32.9 million 
(PAHO, 2007). The increasing obesity epidemic, however, may cause those numbers to 
be even higher. Previous research shows that the prevalence of DM in various Latn 
American countries is (listed from highest to lowest): Nicaragua (11.9%); Guatemala 
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(10.7%); Costa Rica (10.7%); El Salvador (9.8%); Honduras (8%); and Chile (7%) 
(PAHO, 2007). Despite the economic hardships faced by the countries in Latin America, 
there is a need for more efforts in diabetes prevention and control. In 2000, it was 
estimated that 339,035 deaths were caused by diabetes mellitus in Latin America 
(Barceló, Aedo, Rajpathak, & Robles, 2003). The total annual costs associated with 
diabetes, including medications, hospitalizations, consultations, and care for 
complications, were estimated as 65,216 million US dollars (Barceló et al., 2003).   
 The typical Latin American diet, regardless of Hispanic subgroup, tends to be 
high in fiber. The traditional diet consists largely of beans and rice, fresh fruits and 
vegetables, and meats such as beef, pork, and chicken. Fish is also eaten in moderation, 
where available. Corn tortillas are a staple food, especially in Central America. A normal 
Central American breakfast may include coffee sweetened with sugar, sweet bread of any 
kind, fried bacon, refried beans, fried plantains with cream, and corn tortillas, which are 
usually homemade and fried in a pan with or without oil. A lunch may include corn 
tortillas, carne asada or carne fritas, which is grilled or fried meat, respectively, or 
possibly fish, and refried beans. At about 3 p.m., a merienda (snack) is eaten that usually 
consists of sweetened coffee and sweet bread. Then for dinner, the typical meal is corn 
tortillas, refried beans, and meat (McDonald, 2009).  
Typical meals in South America follow the same pattern as in Central America, 
that is, three meals are always eaten – breakfast, lunch, and dinner, and a snack for some, 
mostly children. However in the rural areas, only two meals are normal. Breakfast is 
typically bread-based, being made mostly from corn and cassava. Breads such as arepas, 
which are cooked on the griddle, humitas, which are steamed, and casabe, also cooked on 
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the griddle, are very popular. A very important part of breakfast is coffee, consumed 
alone or with milk. Lunch in South America would not be lunch if there is no soup. Soup 
is often eaten as the first course in a meal, or for some it is the only dish eaten. The soup 
is usually followed by fried meat or fish, vegetables, rice and beans, and fried plantains. 
Dinner is considered to be the most important meal of the day in the continent. Typical 
dishes often include stews, fried foods, roasts, and salads prepared by different methods. 
Beef, pork, and poultry are the most widely consumed meats. Dishes vary by country. 
Lastly, the most common dessert in all South American countries is Dulce de leche 
(Lovera, 2005). 
Adults in Costa Rica with a dietary pattern such as that mentioned above were 
found to have an increased risk of myocardial infarction (MI) and low levels of plasma 
HDL (Martínez-Ortiz et al., 2006). Although traditional, (Bermudez & Tucker, 2003) 
found that food consumption patterns across Latin America are changing. There has b en 
in increase in the intake of total fats, animal products, and sugar, while the consumption 
of cereals, fruits and some vegetables has rapidly declined. These dietary changes are 
increasing the prevalence of chronic diseases and burdening the health systems. For 
instance, “changes in Guatemalan food patterns and in nutrient intakes are marked by 
increased food variety, at the expense of reduction in the consumption of nutrient-dense 
foods and increase in the consumption of processed foods (Bermudez, Hernandez, 
Mazariegos, & Solomons, 2008).”  
It is important to know that there is no one “Hispanic diet.” “The various Hispanic 
groups all have their own nutritional habits and key dishes, based on customs and the 




According to the U.S. Census, as of July 2006 the Hispanic population reached 
approximately 44.3 million (14.8% of the total population) (U.S. Census Bureau, 2006). 
The statistics proved there to be enormous growth in this group of people. From 2000 to 
2006, the growth rate of Hispanics was 24.3%, which is almost four times that of the 
growth rate of the total population in the nation (U.S. Census Bureau, 2006).The trend of 
growth of Hispanics in the U.S. has been continuously increasing. It is projected tha  by 
the year 2050, the Hispanic population will reach 102.6 million, nearly one-quarter of the 
total population. Mexicans make up nearly 64% of the Hispanic population, followed by 
Puerto Ricans (9.0%), Central Americans (7.6%), South Americans (5.5%), Cubans 
(3.4%), and then Dominicans (2.8%) (U.S. Census Bureau, 2006). Of the 3.3 million 
Central Americans, 1,240,031 are Salvadoran, 780,191 are Guatemalan, 466,843 are 
Honduran, 275,126 are Nicaraguan, 141,286 are Panamanian, 111,978 are Costa Rican, 
and the remaining 99,422 are from other Central American countries. South Americans 
total 2.4 million, with the majority being from Colombia (723,596), followed by Ecuador 
(432,068), Peru (415,352), and then Argentina (189,303) (Passel, 2006). It is estimated 
that 796,000 Hispanics reside in Washington D.C., Maryland, and Virginia (Pew 
Hispanic Center, 2006).  
 It was reported in 2005 that the number of newly arrived “unauthorized” 
immigrants had increased the U.S. population by an average of 700,000 – 800,000 a year 
over the past decade. The U.S population was equally increased by legal immigrants over 
the same interval (Passel, 2005). This information indicates that two-thirds of all 
“unauthorized” immigrants have been in the country less than 10 years. National 
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estimates from 2006 show the current total of unauthorized immigrants to be about 8 to 9 
million (Passel, 2006). The vast majority of immigrants have consistently been from 
Mexico; however, those arriving from Central America are increasing much ore 
rapidly. The amount of unauthorized Central American immigrants increased by about 
465,000 over a period of five years from 2000 to 2005 (Passel, 2006).  The demographics 
of this group of immigrants are men and women between the ages of 18-39 years, and 
children. Nearly 49% or 5.4 million of this population is male, 29% or 3.9 million is 
female, and the remainder is children, which account for nearly 1.8 million or 16% of the 
new population. Not included in the total for “unauthorized” children are the 3.1 million 
children born in the U.S. to “illegal” immigrant parents. The data shows that a very small 
percentage of unauthorized immigrants are over the age of 40, while none are over the 
age of 65 (Passel, 2005).  
With the number of unauthorized immigrants increasing, the amount of tax dollars 
spent to treat and care for this population is also increasing concurrently. It is suspected 
that there will be a tremendous financial impact that this growing population will have on 
education and health care costs, especially in treating CHD and MS. Many immigrants 
come to the U.S. in search of a better life and financial opportunities. However, much of 
the population either does not work or have jobs that offer low wages and require little 
education. The Pew Hispanic Center estimates that there were 7.2 million unauthorized 
workers in 2005. The majority of the workers are employed in the following occupations: 
Farming, cleaning, construction, food preparation, production, and transport (Passel, 
2006). These unauthorized workers have a low income and many of the jobs do not 
provide health care benefits. Most immigrants that have no health insurance seek 
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assistance from organizations that offer free or low cost services, such as the Spanish 
Catholic Center located in Washington, DC. 
 
Hispanic Health in the U.S.  
National data on MS and CHD mortality in Central and South Americans is 
limited. According to the National Center for Health Statistics (NCHS), heart disease is 
the number one cause of death among Hispanics accounting for 23.2% of all deaths. This 
is lower compared to the percentage of deaths from heart disease in non-Hispanic whites 
and non-Hispanic blacks, which is 28.6% and 26.5%, respectively (National Centers for 
Health Statistics [NCHS] & Centers for Disease Control and Prevention [CDC], 2002).              
 The San Antonio Heart Study, a population-based study of cardiovascular disease
and diabetes among Mexican Americans in San Antonio, Texas has provided much of the 
data and knowledge on health issues concerning Hispanic Americans. A study looking at 
the trend in the prevalence of MS and its impact on CVD incidence conducted by 
(Lorenzo, Williams, Hunt, & Haffner, 2006), showed that the prevalence of MS had 
increased over time. MS risk factors and socio-demographic data from two cohorts were 
recorded at baseline, 1979-1982 for cohort 1 and 1984-1988 for cohort 2, and then again 
at follow-up, approximately 8 years later. The authors observed that the prevalenc of 
MS was higher at follow-up than at baseline in both cohorts, with noticeably higher rates 
in the second cohort. Participants in cohort 2 had decreased HDL cholesterol, high blood 
pressure, decreased total cholesterol, decreased smoking, less frequent elevated fasting 
blood glucose, equivalent prevalence of type 2 DM, and increased elevated waist 
circumference, as compared to those in cohort 1. When Framingham cardiovascular rik 
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scores were calculated, Mexican American men and women both had significantly higher 
scores than non-Hispanic whites (Lorenzo et al., 2006); (Stern & Wei, 1999). “Thus, the 
prediction is that Mexican Americans of both sexes would have higher cardiovascular 
mortality than non-Hispanic whites (Stern & Wei, 1999).”  
A study, based on data from the Family Blood Pressure Program, comparing 
patterns of MS in four ethnic groups, African Americans, Caucasians, Hispanics, d 
Asians, conducted by (Kraja et al., 2005) showed that over 50% of the Hispanic sample 
surpassed the high density lipoprotein (HDL), blood pressure (BP), and glucose 
thresholds and over 70% surpassed the waist circumference (WC) and triglyceride (TG) 
thresholds for MS risk factors defined by the NCEP. Hispanics had the highest 
prevalence of MS (73%) among all other groups, as well as, the highest concentration of 
serum glucose. A high association of MS with type 2 DM was seen, thus the authors 
concluded that “Hispanics have a trend for being more susceptible to MS (Kraja et al., 
2005).” 
 The Multi-Ethnic Study of Atherosclerosis (MESA), a medical research study 
involving more than 6,000 men and women from six communities in the United States, 
included Hispanic-American participants from Mexico, Dominican Republic, Puerto 
Rico, and Other Hispanic-American countries, with the most common being El Salvador , 
Ecuador, Colombia, and Guatemala (Allison et al., 2008). Based on data from MESA, 
(Allison et al., 2008) conducted a study to determine the prevalence and extent of CVD 
risk factors in four U.S. Hispanic subgroups. This study included 1,437 Hispanic men and 
women enrolled in the MESA study in 2000-2002. Results from this study documented 
that all non-Mexican-American Hispanic subgroups had significantly lower triglyceride 
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levels and lower prevalence of the MS, compared with Mexican Americans. However, 
these same subgroups did not show any significant differences from Mexican Americans 
with regard to fasting blood glucose, systolic blood pressure, nor LDL cholesterol 
(Allison et al., 2008).   
Data from various research studies have reported that Hispanic Americans have 
higher rates of obesity, elevated blood pressure, dyslipidemia, elevated triglyceride 
levels, and diabetes (Mensah, Mokdad, Ford, Greenlund, & Croft, 2005); (Meigs et al., 
2003). However, reports on this population demonstrated lower rates of both CHD and 
total CVD in men and women (Mensah et al., 2005).  “Although they are usually 
classified as a single ethnic group, Hispanics are culturally, socioeconomically, and 
genetically heterogeneous and represent a wide variety of national origins and social 
classes. These differences are manifested in measures of CVD (Allison et al., 2008).” 
 
Metabolic Syndrome Criteria 
 Currently, the MS can be diagnosed using several definitions that have been 
established by a variety of organizations. The most frequently used criteria have been 
defined by: NCEP ATP III, IDF, WHO, and the EGIR (Eckel, Grundy, & Zimmet, 2005).  
The criteria defined by most organizations consist of the following abnormalities in an 
individual: hypertension, insulin resistance, glucose intolerance, hypertriglyceridemia 
(high serum triglycerides), low levels of high density lipoprotein cholesterol (LDL-c), 
and abdominal obesity (Okosun, Liao, Rotimi, Prewitt, & Cooper, 2000). Each of the 
organizations listed has a unique criterion for abdominal obesity. The cutoff values are 
>102 cm (>40 in.) in men and >88 cm (>35 in.) in women for ATP III. The cutoff values 
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for IDF are ≥94 cm for Europid men and ≥80 cm for Europid women, with ethnicity 
specific values for others. WHO uses waist-to-hip ratio >0.9 in men and >0.85 in women 
and/or BMI >30 kg/m2. The cutoff values for EGIR are ≥94 cm in men and ≥80 cm in 
women (Li & Ford, 2006). Medical professionals prefer to use simple tools with which to 
assess their patients, and therefore prefer to use the NCEP ATP III definition; most agree 
that it is simpler for clinical use (Eckel et al., 2005).   
 
Waist Circumference 
A commonality among those who have acquired risk factors for the MS is 
abdominal obesity. The ATP III report states, “Most persons with insulin resistance have 
abdominal obesity (ATP III).” Obesity, particularly in the abdominal region, affects many 
Americans, especially Hispanic Americans. Abdominal obesity (assessed by waist 
circumference (WC)) may be a better indicator of increased CHD risk than overall excess 
bodyweight (Sarti & Gallagher, 2006). 
Ford, Mokdad, and Giles (2003) found that trends in WC in the U.S. had 
increased from 27.7% in NHANES III (1988-1994), a nationally representative sample of 
the U.S., to 36.0% in NHANES 1999-2000, a change of 8.3%. In a 2007 follow up study 
of the trends in WC, the authors found that over one-half of U.S. adults had abdominal 
obesity in the NHANES 2003-2004 (Li, Ford, McGuire, & Mokdad, 2007). In a 2003 
study, Ardern, Katzmarzyk, Janssen, & Ross (2003) tested the use of the U.S. National 
Institutes of Health (NIH) guidelines for determining metabolic risk factors, which 
advocated risk stratification based on WC measurements within BMI categories as a 
means to capture those at increased cardiovascular risk. They found that the prevalence of 
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MS nearly doubled in overweight subjects with a high WC compared with subjects with a 
low WC.  
This epidemic problem has created much controversy with respect to WC cutoffs 
that have been established by various organizations for metabolic syndrome criteria. Th  
WC cutoffs were made based on evidence compiled from various research studies in 
Caucasian populations (Banerjee & Misra, 2007). WC cutoffs for Hispanics have not 
been determined and remain unknown (Zhu et al., 2005). Therefore, the established WC 
cutoffs may not be applicable to Central and South Americans when being evaluated for 
the MS. In April of 2005, IDF proposed a new definition of the MS in response to the 
proliferation of definitions (Ford, 2005). They hoped it would serve as a worldwide, 
unifying definition. In their criteria they proposed several ethnic specific WC cut offs. 
The values are as follows: ≥ 94 cm and ≥ 80 cm for Europids; ≥ 90 cm and ≥ 80 cm for 
South Asians (based on a Chinese, Malay, and Asian-Indian population); ≥ 90 cm and ≥ 
80 cm for Chinese; and ≥ 85 cm and ≥ 90 cm for Japanese, all values are for males and 
females, respectively. Ethnic South and Central Americans are to use the 
recommendations for South Asians until more specific data are available. Sub-Saharan 
Africans and Eastern Mediterranean and Middle East (Arab) populations are to use 
European data until specific data becomes available (Alberti, Zimmet, & Shaw, 2005). 
The IDF recognizes that not all population groups are the same. By suggesting varyi
cutoffs, this allows for adjustment of WC to lower thresholds when ethnic groups are 






Elevated fasting blood glucose (FBG) is commonly known for being used to 
diagnose DM; however, it is also an important criterion for diagnosing MS. Some 
organizations with working definitions, specifically WHO and EGIR, have made glucose 
intolerance, insulin resistance, or diagnosed DM an obligatory criterion. Whereas oth r 
organizations like ATP III, view all risk factors equally (Li & Ford, 2006). Standardized 
diagnostic criteria are used to categorize people without diagnosed diabetes as to whether 
they have diabetes, impaired fasting glucose or normal blood glucose levels. Persons with 
FBG levels >126 mg/dL on more than one occasion, are diagnosed with diabetes. FBG 
levels ≥100-125mg/dL indicate impaired fasting glucose. Impaired fasting glucose (IFG) 
is usually an indicator of insulin resistance, along with other metabolic risk factors. 
According to ATP III, (NCEP ATP III, 2002), “A portion of persons with impaired 
fasting glucose will eventually develop type 2 diabetes, which further enhances the risk 
for CHD.” FBG levels 70-99 mg/dL are considered normal.  
FBG tests are more commonly used than non-FBG tests for more precise results.
In assessing the prevalence of DM in the U.S. population using NHANES 1999-2002, 
(Cowie et al., 2006) only included those who had fasted for 8 to < 24 hours in the 
analyses. The results of this study showed that Mexican-Americans, aged ≥ 20-59 years, 
have the highest rates of IFG compared to their non-Hispanic white and non-Hispaic 
black counterparts. In a sample of 1,304 Puerto Ricans living in New York City, the 
prevalence of DM was 28.2% for those aged 18-44 years, 38.9% for those aged 45-64 
years, and 39.2% for ages 65 years and up (Melnik et al., 2004). These data reflect a 
growing concern for the elevated risk factors commonly seen in Hispanic groups.  
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High Density Lipoprotein Cholesterol 
High levels of plasma HDL cholesterol tend to be a negative risk factor for 
developing CVD. For that reason, it is known as the “good” cholesterol. HDL participates 
in reverse cholesterol transport, which removes cholesterol, typically LDL, from the 
peripheral tissues and takes it to the liver for excretion, metabolism, and storage. Levels 
of HDL cholesterol can be affected by existing conditions, such as insulin resistance and 
type 2 DM. Research has shown that the greater the degree of hyperinsulinemia, the 
lower the HDL cholesterol concentrations (Reaven, 2006). Previous studies have found 
that low plasma levels of HDL cholesterol contribute to an increased cardiovascular risk 
and are a predictor of CHD, and suggest that HDL cholesterol may even be an 
independent risk factor (Ryder et al., 2007). Low HDL cholesterol increases CHD risk 
regardless of the LDL cholesterol level (Barter & Rye, 1996). 
Low HDL cholesterol levels are very common among the Hispanic American 
population, especially in Central and South America. This has been demonstrated by 
study findings in Venezuela, where 50.3% of the black Hispanic men and 71.8% of 
women had low HDL cholesterol; while 50.8% of mixed Hispanic men and 56.2% of 
women had low HDL cholesterol levels, as defined by NCEP ATP III criteria (Ryder et 
al., 2007). Similar results were also seen in Chile (Espinosa-Larranaga, Vejar-Jalaf, & 
Medina-Santillan, 2005) and Guatemala (Gregory, Dai, Ramirez-Zea, & Stein, 2007), 
where the prevalence of low HDL-cholesterol was 39.0% of the total population and 75% 
of men and 87% of women, respectively. Despite the overwhelming evidence for HDL 
cholesterol as an independent risk factor for CHD, the importance of HDL cholesterol 
levels lower than 40 mg/dL for men and lower than 50 mg/dL for women seems to be 
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overlooked. LDL cholesterol takes precedence, largely when it comes to pharmacological 
management. Non-pharmacological therapies such as reducing smoking, healthy di ts 
(consisting of 50 to 60% carbohydrates and 10 to 15% protein and fats), maintenance of 
BMI < 25 kg/m2, and increasing exercise have a positive influence in elevating plasma 
HDL cholesterol levels (Espinosa-Larranaga et al., 2005). 
 
Triglycerides 
Elevated plasma triglycerides (TG), also known as hypertriglyceridemia, serve as 
a marker for atherogenic remnant lipoproteins and other lipid and nonlipid risk factors in 
the MS (NCEP ATP III, 2002). In the U.S., hypertriglyceridemia is most prevalent 
among Mexican-Americans (Ford, Giles, & Dietz, 2002); however it can also be 
observed in other Hispanic ethnic groups. Results from the Prevencion Study in Peru 
showed that an average of 52.0% of the male participants was suffering from high TG. 
This study demonstrated that increasing age is associated with a significant increase in 
high triglycerides (Medina-Lezama et al., 2007).  
 
Blood Pressure 
Hypertension (HTN) is defined by ATP III as systolic blood pressure ≥130 mmHg 
or diastolic blood pressure ≥85 mmHg. HTN is a significant public health burden in that 
it increases CVD morbidity, mortality, disability, and economic cost (Gu, Burt, Paulose-
Ram, Yoon, & Gillum, 2008). There is an unequivocal association between blood 
pressure and the risk of CVD. HTN often occurs concomitantly with elevated total 
cholesterol (NCEP ATP III, 2002). According to data from the NHANES III, Gu et al., 
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(2008) determined that participants who were pre-hypertensive and hypertensive were 
more likely to be male, obese, older, have diabetes, hypercholesterolemia, congestive 
heart failure, chronic kidney disease, and have had a prior stroke and previous heart 
attack. These data were taken from 16,917 participants aged 18 years and older who had 
mortality follow-up information. The mean blood pressure for hypertensives was 145/81 
mmHg (23.7%), 125/77 mmHg for prehypertensives (30.8%), and 109/68 mmHg for 
normotensives (Gu et al., 2008). Research conducted in Venezuela revealed that HTN 
was one of the three most frequent components used to diagnose MS (Florez et al., 2005). 
Approximately 38.1% of the total population had HTN.  
   
Metabolic Syndrome and Cardiovascular Diseases 
 CVD is a class of diseases that involves the heart and blood vessels and affects 
the cardiovascular system. CVDs include coronary heart disease (heart attacks), 
cerebrovascular disease (stroke), raised blood pressure (hypertension), peripheral artery 
disease, rheumatic heart disease, congenital heart disease and heart failure. The major 
causes of cardiovascular disease are tobacco use, physical inactivity, and an unhealthy 
diet. Among these causes is also the MS. Studies have confirmed that the metabolic 
syndrome may increase the risk of developing CVD by as much as 4-fold.  Presence of 
the metabolic syndrome also increases morbidity and mortality in patients both with and 
without clinical evidence of CVD (Clark & El-Atat, 2007). Previous research suggests 
that CVD risk factors have an additive effect on risk for CVD; the same is generally true 
for MS components and for risk of CVD and type 2 diabetes (Wilson, D'Agostino, Parise, 
Sullivan, & Meigs, 2005). In a study by Isomaa et al. (2001), the presence of MS was 
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associated with an approximately threefold higher risk of coronary heart disease, 
myocardial infarction, and stroke in all subjects, and this risk was greater than the risk 
associated with any of the individual components.  
 CHD accounts for approximately 52% of all diagnosed cardiovascular diseases in 
the U.S., thus contributing to the high CHD mortality rate. There are several risk factors 
for CHD. Risk factors are diseases, physiologic states, biologic markers, or other 
identifiable factors that are associated with an increased incidence of CVD in populations 
that have these risk factors (Eaton, 2005). Among the risk factors is DM, which is an 
independent risk factor and has become increasingly important in the U.S. This is 
because of the increasing rates of obesity, aging of the population, and the growth of 
ethnic populations that are susceptible to developing type 2 DM (Grundy et al., 2001). 
Coronary atherosclerosis, caused by elevated blood cholesterol levels, 
hypercholesterolemia, is known to cause CHD. However, there are other traditional and 
emerging risk factors that are classified as modifiable or non-modifiable.  
The traditional risk factors are age, gender, family history, cigarette smoking, 
hypertension, hyperlipidemia, diabetes mellitus, physical inactivity, diet, alcohol 
consumption, obesity, and left ventricular hypertrophy. Of those traditional risk factors, 
the non-modifiable risk factors are age, gender, and family history of the disease; all else 
can be modified through diet, exercise, and medication (Eaton, 2005). The emerging risk 
factors are highly sensitive C-reactive protein, homocysteine, lipoprotein (a), and 
fibrinogen (Eaton, 2005), as well as, proinflammatory cytokines, including interleukin-6 
(IL-6) and tumor necrosis factor-α (Hanley et al., 2004; Langenberg, Bergstrom, Scheidt-
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Nave, Pfeilschifter, & Barrett-Connor, 2006). Traditional and emerging risk factors play 
integral roles in the occurrence of coronary events.  
With increases in prevalence around the world, it is likely that “the MS will be 
one of the most prevalent diseases of mankind, and one of the most costly in its 
contributions to morbidity and premature mortality, particularly from atherosclerosis and 
other cardiovascular diseases” (Hansen, Saye, & Wennogle, 1999). 
 
Metabolic Syndrome and Type 2 Diabetes Mellitus 
 Diabetes mellitus and its precursors of insulin resistance and glucose intlera ce 
are potent risk factors for CVD and mortality, as well as microvascular complications 
(DeFronzo, Ferrannini, Keen, & Zimmet, 2004; Haffner, 2006). People with diabetes are 
two to four times more likely to develop CVD due to a variety of risk factors, including: 
high blood pressure, lipid disorders, high LDL cholesterol, high triglycerides, low HDL 
cholesterol, smoking, obesity, and lack of physical activity (Rosamond et al., 2008). The 
majority of these risk factors are criteria included in all definitions of the MS. The 
increasing obesity rates in the US have tremendously increased the risk of devel ping 
insulin resistance. It has been proven that hyperinsulinemia, hypertension, and 
dyslipidemia are linked (DeFronzo et al., 2004); thus once you’ve developed one of them, 
the others will soon appear. This corresponds strongly with the notion that the MS 
enhances the risk for type 2 diabetes. According to the National Diabetes Education 
Program (NDEP), about 2.5 million or 10.4% of Hispanic and Latino Americans over the 
age of 20 years have been diagnosed with diabetes. (National Diabetes Education 
Program [NDEP], 2008). 
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A study that investigated the clustering of metabolic and inflammation variables 
using data from the Insulin Resistance Atherosclerosis Study (IRAS) on nondiabetic 
participants to determine the association of the clusters with risk of developing ty e 2 
DM over time found that three factors, metabolic, inflammation, and blood pressure, 
emerged during the analysis as significant predictors for DM. Each factorwas interpreted 
based on factor loadings of ≥ 0.40 of certain inflammation and metabolic syndrome 
variables. Insulin sensitivity was present in both the metabolic and inflammation clusters. 
The results showed that “these factors were generally consistent across sex and ethnic 
subgroups, and each factor was found to be significantly associated with progression to 
diabetes over the follow-up period of 5.2 years (Hanley et al., 2004).” It is unequivocal 
that type 2 diabetes is associated with an increased cardiovascular risk. 
Diabetes is the most potent CHD risk factor and is viewed as a CHD equivalent (Man , 
Lee, Youlian Liao, & Natarajan, 2006).   
 
Summary 
 The Hispanic American population, specifically those from Central and South 
America, is dramatically increasing in the U.S. Central and South Americans are the 
fastest growing group of Hispanics in the U.S., with the second largest population. 
However, there is limited MS and CHD data on this rapidly growing group. National 
data, such as NHANES, has studied more established Hispanic Americans of Mexican, 
Puerto Rican, and Cuban descent. Data on Mexican Americans suggests that they have 
greater risk of cardiovascular mortality than non-Hispanic whites, contrary to what was 
previously thought (Stern & Wei, 1999). CHD morbidity and mortality has become 
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increasingly prevalent among the Hispanic population in the U.S. MS risk factors have 
contributed substantially to the increased incidence of heart disease. This study will 
ascertain whether Central and South Americans living in the Washington, D.C. area have 





































Chapter 3: Methods 
A cross-sectional survey was conducted to assess the prevalence of MS and its 
individual components in a sample of participants attending the Spanish Catholic Center 
(SCC) Medical Clinic in Washington, D.C.  
 
Subjects  
 Data were collected by medical record extraction from files at the SCC 
Washington, D.C. Medical Clinic. Permission was granted by the SCC and obtained from 
the Institutional Review Board at the University of Maryland, College Park.   
 The SCC is a private, non-profit agency serving Latino’s and the immigrant 
community. They have locations in Washington, D.C. and Montgomery County, 
Maryland, with a total of four clinics (Catholic Charities, 2008). Data for this study were 
obtained from the Washington, D.C. clinic, which is in a heavily Hispanic neighborhood. 
Services offered at the medical clinics include primary care, gynecology, cardiovascular 
risk programs, including a diabetes clinic and heart program, cancer prevention program, 
and referrals (Catholic Charities, 2008). The majority of the patients that visit the clinic 
are adults of Hispanic origin, primarily from El Salvador. Services are provided based on 
income, and are usually free or low cost. In 2007, 6,232 patients were served at the SCC. 
In 2008, 1,713 new patients were served at the SCC’s D.C. medical clinic alone, in 
addition to continuing patients (Catholic Charities, 2008). The SCC is funded by the 
United Way, the Archdiocese of Washington, D.C., and private and public donations 





 A questionnaire was used to obtain background information about the patients 
(Appendix A).  The data included demographic and socio-economic information reported 
by the patients, anthropometric and clinical data taken by the SCC staff, and biochem cal 
data obtained from fasting blood and urine tests. Biochemical indices were analyzed by 
Quest Diagnostics Incorporated in Baltimore, Maryland. Quest Diagnostics uses 
standardized blood analysis techniques. Concentrations of fasting plasma lipids and 
glucose were measured using standardized blood analysis techniques. Blood glucose was 
analyzed using an automated enzymatic method (Caraway & Watts, 1986). Cholesterol 
and HDL cholesterol were both analyzed enzymatically. Triglyceride levels w re 
analyzed by automated spectrophotometry (Stein, 1986). Low density lipoprotein 
cholesterol was mathematically derived using the Friedewald formula for subjects with 
triglyceride levels of 400 mg/dL or less (Friedewald, Levy, & Fredrickson, 1972).   
The SCC maintained active records alphabetically for three years (2006-209). 
On each occasion data were collected, medical records were extracted by systematic 
sampling. In systematic sampling, the researcher can have a single starting point, where 
the first record is chosen randomly and then all remaining records are chosen at ev ly 
spaced increments (Quinn & Keough, 2002). After the initial record was chosen, every 
third record was subsequently selected to be included in the sample (n = 1,044). Of those 
active medical records, only records of participants from Central and South America with 
fasting blood analyses were extracted. Subjects were identified by an identification 





 Descriptive and inferential statistics were used in the analysis. Data were 
presented as means ± standard deviations for continuous variables and as frequencies and 
percentages for categorical variables. Differences between mean values of MS 
components based on country of origin, BMI category, and year of attendance at the 
medical clinic were assessed by analysis of variance (ANOVA), with a Tukey-Kramer 
post-hoc test to accommodate groups with unequal sample sizes. Chi Square test was 
used to compare prevalence rates of MS and MS components in analyses stratified by 
gender and BMI. Student’s t test compared independent means between men and women 
for selected variables. All tests were two-tailed. A significance lev l was set at p ≤ 0.05, 
and analyses were performed using Statistical Analysis System (SAS)Version 9.2; SAS 












Chapter 4: Results 
A) Prevalence of the metabolic syndrome in Central and South 
American residents in the Washington, D.C. area 
 
 
Abstract   
 
Background:  The Central and South American population is growing rapidly in the U.S., 
but little information is known about the health status of this population.   
Objectives:  The purpose of this study was to ascertain which metabolic abnormalities are 
most associated with the metabolic syndrome (MS) in this population, and to estimate the 
prevalence of MS and its individual risk factors and then compare differences in th  r sk 
factors among various Hispanic sub-groups of both genders. 
Design:  This cross-sectional, medical record extraction survey sampled 1,042 adult 
patients of the Spanish Catholic Center (SCC) Medical Clinic in Washington, DC.  A 
questionnaire was used to collect sociodemographic, medical history, anthropometric, 
biochemical, and clinical data.  In this study, the prevalence rates of MS and its 
components were estimated using modified NCEP-ATP III guidelines that included a 
BMI ≥ 25 kg/m2 as a criterion.   
Results:  The overall prevalence of the metabolic syndrome in our study population was 
28%.  The most common abnormal metabolic indicator was an elevated BMI ≥ 25 kg/m2 
(75.6%).  The results showed that 43.2% of men and 50.7% of women had HDL levels 
lower than normal, while the prevalence of hypertriglyceridemia was 37%.  The risk of 
abnormal metabolic syndrome indicators increased steadily as BMI increased.  The 
combination identifying the most subjects with the MS included the following: high 
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triglycerides, low HDL cholesterol, and overweight (BMI ≥ 25-29 kg/m2) and obesity 
(BMI ≥ 30 kg/m2) (n = 85 men; n = 136 women).  Among the five most frequently 
reported Hispanic sub-groups, the prevalence of MS was 29.4%, which was a total of 255 
subjects.  Rates were highest among subjects from El Salvador, Honduras, Peru, and 
Guatemala, 30.7%, 29.0%, 29.6%, and 30.1%, respectively; and lowest among subjects 
from Bolivia (18.3%).  Women had higher BMI, lower HDL cholesterol, but a lower 
prevalence of metabolic syndrome.   
Conclusion:  Our results indicate that the pattern of chronic disease risk, dyslipidemia 
and high BMI, increased the likelihood of having the metabolic syndrome, which is 
consistent with studies conducted on Mexican-Americans in the San Antonio Heart Study 




Cardiovascular diseases (CVD) are among the nation’s leading causes of death. 
Of note, “CVD is the leading cause of death among the largest and fastest growing ethnic 
minority in the United States, Latinos/Hispanics” (Davidson et al., 2007). Coronary heart 
disease (CHD) is the leading cause of death in the United States (U.S.), causing 
approximately 53% of all deaths annually (Rosamond et al., 2008). Dietary intake may, 
in part, be responsible for the increasing prevalence of CVD (Martínez-Ortiz et al., 2006). 
Diet affects the risk factors for CHD and many other chronic diseases, including Diabetes 
Mellitus (DM), strokes, and certain cancers (Martínez-Ortiz et al., 2006); all of which are 
among the top ten leading causes of death in the U.S.  
Metabolic Syndrome (MS) is a cluster of metabolic abnormalities that occur
together in an individual and are associated with an increased risk of developing 
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cardiovascular disease (CVD) and type 2 diabetes mellitus (DM) (Meigs et al., 2003). 
The following abnormalities are considered to be characteristic of the syndrome: glucose 
intolerance, hyperinsulinemia, high plasma triglycerides, decreased high-ensity 
lipoprotein (HDL) cholesterol, hypertension, central obesity, proinflammatory s ate, and 
prothrombotic state, all of which increase the risk of developing CVD and diabetes (Ford 
& Giles, 2003). MS is closely associated with a generalized metabolic disorder called 
insulin resistance, in which tissue responsiveness to the normal action of insulin is 
impaired (NCEP ATP III, 2002). Overweight/obesity, physical inactivity, and genetic 
factors are the underlying causes of the metabolic syndrome.  
Each of the MS components alone has detrimental health effects, but when 
combined, the components become more “powerful” (Reaven, 2006) by increasing the 
likelihood of developing CVD.  Each definition of MS possesses, but is not limited to, the 
aforementioned components. The definition of the MS has evolved over time.  However, 
there are five commonly accepted components which are agreed upon by several 
organizations, such as the National Cholesterol Education Program, International 
Diabetes Federation, European Group for the Study of Insulin Resistance, and the World 
Health Organization. 
Much of the known information about chronic diseases in the U.S. has been 
generated by large national studies such as the National Health and Nutrition 
Examination Survey (NHANES).  NHANES is conducted to ascertain the current health
and nutrition status of non-Hispanic whites, non-Hispanic blacks, and Hispanic 
Americans of Mexican, Puerto Rican, and Cuban descent living in the U.S. Despite the 
wealth of information on these established Hispanic Americans, generalizations should 
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not be made to other Hispanic subgroups. According to Nath (2005), “Findings from one 
Hispanic subgroup cannot be applicable or extrapolative to other Hispanic subgroups 
because each subgroup's social histories, cultural identities, health behaviors, and genetic 
compositions are unique.”  
Despite the significant awareness of risk factors for CHD in these commonly 
studied groups of Americans, very little is known about the prevalence of metabolic 
syndrome among Central and South Americans. Central Americans, specifically, are the 
fastest growing group of Hispanics in the U.S., followed by South Americans. 
Furthermore, Central and South Americans made up 7.6% and 5.5% of the total Hispanic 
population in the U.S. in 2006, respectively. Combined, these two groups made up 13.1% 
of the Hispanic population, while Mexican-Americans made up 64% of the total Hispanic 
population of 44,252,278. The total Hispanic population was 14.8% of the total U.S. 
population of 299 million (U.S. Census Bureau, 2006).    
This research will be useful for public health planning, education, as well as 
program implementation that can offer preventative services to Hispanics to reduce isk 
factors for CHD.   
 
 
Subjects and methods 
 
Study population 
A cross-sectional survey was conducted to assess the prevalence of metabolic 
syndrome and its individual components in a sample of participants attending the Spanish 
Catholic Center (SCC) Medical Clinic in Washington, DC.  The SCC is a private, non-
profit agency serving Latino’s and the immigrant community.  SCC has locations in 
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Washington, D.C. and Montgomery County, Maryland, with a total of four clinics 
(Catholic Charities, 2008).  Data for this study were obtained from the Washington, D.C. 
clinic, which is located in a heavily Hispanic neighborhood.  Services are provided based 
on income, and are usually free or low cost.  Our study sample consisted of 1,044 adults 
aged 18 years and older, who reported being from any Central or South American 
country, and who had fasting lipid profile measurements available.  Data were collcted 
by medical record extraction from files at the medical clinic using a questionnaire 
(Appendix A).  On each occasion data were collected, medical records were extracted by 
systematic sampling.  Subjects were identified by an identification number to guarantee 
confidentiality.  Protocols were approved by the SCC and by the Institutional Review 
Board at the University of Maryland, College Park. 
 
Study variables 
A questionnaire was used to obtain sociodemographic information on the patients.  
Sociodemographic variables included date of birth, gender, self-reported country of 
origin, state of residence, education, employment status, and years living in the U.S.   
Lifestyle variables included current smoking status and alcohol consumption.  Medical 
history information was used to assess subjects diagnosed by a physician with diabe es, 
hypertension, or heart problems.   
 
Biochemical measures 
Biochemical indices were analyzed by Quest Diagnostics Incorporated in 
Baltimore, Maryland.  Concentrations of fasting plasma lipids and glucose were 
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measured using standardized blood analysis techniques.  Blood glucose was analyzed 
using an automated enzymatic method (Caraway & Watts, 1986).  Cholesterol and HDL 
cholesterol were both analyzed enzymatically.  Triglyceride levels were analyzed by 
automated spectrophotometry (Stein, 1986).  Low density lipoprotein cholesterol was 
mathematically derived using the Friedewald formula for subjects with triglyceride levels 
of 400 mg/dL or less (Friedewald et al., 1972).   
 
Metabolic syndrome assessment 
Each subject was assessed for the presence of metabolic syndrome using data 
collected on fasting plasma concentrations of glucose, HDL cholesterol, and 
triglycerides, blood pressure, height, and weight.  The metabolic syndrome was defined 
by a modified NCEP-ATP III definition that identified subjects if three or m re of the 
following were present:  (1) BMI ≥ 25 kg/m2, (2) fasting plasma glucose ≥ 110 mg/dl, (3) 
HDL cholesterol < 40 mg/dl for men and < 50 mg/dl for women, (4) triglycerides ≥ 150 
mg/dl, (5) blood pressure ≥ 130/85 mm Hg (NCEP ATP III, 2002).  The World Health 
Organization (WHO) and the American Association of Clinical Endocrinologist (AACE) 
have clinical criteria for MS and for the diagnosis of Insulin Resistance Syndrome (IRS), 
respectively, which use BMI instead of waist circumference.  WHO uses a cutoff of > 30 
kg/m2 and AACE uses a cutoff of BMI ≥ 25 kg/m2 as the body weight component of the 
syndrome (Grundy, Brewer, Cleeman, Smith, & Lenfant, 2004).  In this study, the AACE 
BMI cutoff was used.  BMI was calculated as weight divided by the square of height with 
available measurements and was categorized into four groups: underweight (< 18.5 
kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2), and obese (> 
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30.0 kg/m2), according to WHO criteria (World Health Organization, 1995).  We 
excluded underweight subjects with a BMI < 18.5 kg/m2 (n = 1) and subjects receiving 





 Descriptive and inferential statistics were used in the analysis. Data were 
presented as means ± standard deviations (SD) for continuous variables and as 
frequencies and percentages for categorical variables. Differences between mean values 
of MS components based on country of origin and BMI category were assessed by 
analysis of variance (ANOVA), with a Tukey-Kramer post-hoc test to accommodate 
groups with unequal sample sizes. Chi Square test was used to compare prevalence rates 
of MS and MS components in analyses stratified by gender and BMI. Student’s t t s  
compared independent means between men and women for selected variables. All test 
were two-tailed. A significance level was set at p ≤ 0.05, and analyses were performed 
using Statistical Analysis System (SAS) (Version 9.2; SAS Institute Inc., Cary, NC). 
 
Results 
 A total of 1,042 men and women were chosen for our study.  A physical exam 
found that subjects were in good general health.  The majority were women (n = 704; 
67.6%).  Ages ranged from 18 to 87 years, with a mean age and SD of 42 and 13 years, 
respectively.  Anthropometric, biochemical, and clinical characteristics stratified by 
gender are shown in Table 4.1.  Both men and women were similar in age; however, 
women were slightly older.  A large number (33.7%) of subjects in the study were 34 
years or younger (n = 351).  Women had a significantly higher BMI than men (p ≤ 0.05).  
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Table 4.1 shows that the mean TG value in men, as well as mean LDL cholesterol in men 
and women, exceeded the ATP III cutoff criteria for optimal levels.     
Country of origin was subject reported (Appendix B).  Nearly 50% of the study 
population reported being from El Salvador.  Results indicate that the majority of subject  
resided in Maryland (57%) at the time of the study and were employed with a median 
income of $13,000 per year.  Most of the subjects were either married (45%) or single 
(42%).  Of those who had dependents, the average number was 2.6 and 2.3 for men and 
women, respectively.  A total of 69% of subjects had primary or secondary education, 
while only 23% spoke English fluently.  Only about 100 (11%) subjects had medical 
insurance.  The average number of years that subjects had been living in the U.S. was 8.8 
years.    
Table 4.2 shows the prevalence of individual metabolic syndrome components 
among males and females in the study sample.  These results indicate that the most 
common abnormal indicator of the metabolic syndrome was a high BMI ≥ 25 kg/m2, as 
used in the AACE definition, for both men and women.  High fasting plasma glucose 
concentrations were infrequently seen in both men and women, with a prevalence rate of 
only 9.7%, compared to the 75.6% for high BMI.  HDL cholesterol was analyzed 
separately for men and women.  The results showed that 43.2% of men had HDL 
cholesterol levels lower than recommended.  The results for the women showed that just 
over half of them had lower than normal HDL cholesterol levels.  The overall percentage 
of both men and women with hypertriglyceridemia was 37%.  Over half (59%) of those 
subjects were women.  Of the 338 men, 46.5% actually had hypertriglyceridemia, 
compared to 32.5% of all women.  The overall prevalence of hypertension was 9.6% 
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among men and women. Of the 23.4% of subjects who had a systolic blood pressure at or 
above to 130 mmHg, 36.1% were men and 63.9% were women.  As for an elevated 
diastolic blood pressure, only 11% of subjects met or exceeded this criterion.   
Among men, 29.3% had one abnormal component, 26.0% had two abnormal 
components, 26.9%, 5.9%, and 1.2% had three, four, or all five abnormal components of 
the metabolic syndrome.  When compared to men, these percentages were generally 
higher for women, with values of 29.7, 19.7, 19.9, 4.7, and 0.4%, respectively.  The total 
prevalence of MS in our study population was 28% (n = 291).  The prevalence for men 
was 11% (n= 115) and the prevalence for women was 17% (n = 176).   
A chi-square test of independence was performed to examine the relation between 
elevated BMI and sex.  The relation between these variables was significant, X2 (1, N = 
1042) = 6.03, p < 0.05.  However, this association was significant only for a BMI of ≥ 30 
kg/m2, not for a BMI ≥ 25 kg/m2.   
 
BMI category as a predictor of MS risk 
 Table 4.3 presents the prevalence of MS risk components by BMI category 
(normal, overweight, obese) in the overall study population.  Across all MS components, 
TG, HDL, BP, and blood glucose, subjects with a BMI of ≥ 30 kg/m2 had significantly 
higher prevalence rates than subjects with BMI values < 30 kg/m2.  The number of obese 
subjects that met MS criteria for each component was nearly three times that of subjects 
with normal BMI.  Comparisons between BMI categories were made with Chi-Square 




Identifying MS by BMI category 
All possible combinations of three of the five NCEP-ATP III criteria used to 
diagnose MS are shown in Table 4.4.  The presence of MS varied significantly by the 
specific criteria used.  The results reveal that being overweight (BMI ≥ 25 kg/m2) or 
obese (BMI ≥ 30 kg/m2); in combination with hypertriglyceridemia and low HDL 
cholesterol was the most prevalent type of MS for both men and women.  BMI, TG, and 
HDL identified 85 men and 136 women.  There was a statistically significant differenc  
between BMI category and the BMI, TG, and HDL combination of MS for both men and 
women (p < 0.05).  The combinations identifying the most subjects with MS included 
having a BMI ≥ 25 kg/m2, low HDL, high triglycerides, and high blood pressure.  The 
combination that captured the least amount of subjects was HDL, blood pressure, and 
glucose (n = 8).   
 
Differences in MS risks among Hispanic sub-groups 
 The prevalence of MS among the five most frequently reported countries of origin 
is shown in Table 4.5.  The prevalences of having only one, two, three, four or all five 
MS components for subjects from El Salvador, Honduras, Peru, Guatemala, and Bolivia 
are also shown in the table.  Among these five Hispanic sub-groups, the prevalence of 
MS was 29.4%, which was a total of 255 subjects.  The overall prevalence of MS was 
very similar among subjects from El Salvador, Honduras, Peru, and Guatemala, with 
prevalence rates of 30.7%, 29.0%, 29.6%, and 30.1%, respectively.  Subjects from 
Bolivia had a substantially lower MS prevalence of 18.3%.  We also estimated the 
prevalence of the MS for males and females in the five most frequently reported c untries 
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of origin, and the results are shown in Table 4.6.  We found that a greater percentage of 
male subjects had the MS, with the exception of Bolivians, where only 7.1% (n = 1) of 
male subjects and 21.7% (n = 10) of female subjects had the MS.   
 
Discussion 
 The overall prevalence of metabolic syndrome in our study was 28%.  Male 
subjects had a MS prevalence of 34.0%, while the prevalence for female subjects was 
25.0%.  In the NHANES 1999-2002, results from data collected on Mexican-American 
men and women showed that the prevalence of metabolic syndrome according to the 
NCEP-ATP III definition was 32.2 and 37.8% for men and women, respectively (Ford, 
2005).  Furthermore, in the San Antonio Heart Study (SAHS), Lorenzo et al. (2007) 
found the prevalence of NCEP-ATP III metabolic syndrome to be 29.6% for men and 
30.9% for women among Mexican-Americans.  Several studies conducted on Mexican-
Americans have also found similar prevalence rates of the metabolic abnormalities of the 
metabolic syndrome (Ford, 2005; Ford & Giles, 2003; Lorenzo, Williams, Hunt, & 
Haffner, 2007; Lorenzo, Williams, Hunt, & Haffner, 2006).  In a study of U.S. adults 
aged ≥ 20 years, the prevalence rates of hypertriglyceridemia, low HDL cholesterol, 
hypertension, and high glucose were 40.2%, 34.1%, 39.8%, and 21.1%, respectively 
among Mexican-American men.  Among the Mexican-American women studied, the 
rates for the same abnormalities were 35.8, 46.6, 32.9, and 32.9%, respectively (Ford & 
Giles, 2003).  Our study subjects had a lower prevalence of metabolic syndrome, but 
consistent with the NHANES and SAHS studies, the prevalence of MS was higher in 
women.   
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In this cohort of Central and South Americans, the most prevalent metabolic 
abnormalities were elevated BMI (78.4% men and 74.9% women), hypertriglyceridemia 
(46.5% men and 32.5% women), and low HDL cholesterol (43.2% men and 50.7% 
women).  High fasting plasma glucose levels were not as frequent as one might expect in 
a population in which 78% of its subjects had a BMI at or above 25 kg/m2.  A correlation 
analysis examining whether BMI and blood glucose vary together was performd.  Our 
results revealed that there was a weak, positive correlation between the two variables (r = 
0.11).  Previous studies have shown that “the heavier the person, the more likely he or 
she is to be insulin resistant” (Reaven, 2006), and that adiposity and insulin resistanc are 
correlated (r = 0.6) (Reaven, 2006).  (Vazquez, Duval, Jacobs, & Silventoinen, 2007) 
found that general obesity is a good predictor of diabetes among white U.S. and European 
populations.  No differences were found in the prevalence of high BMI (≥ 25 kg/m2) 
between men and women; however, hypertension and high glucose levels were both more 
frequently seen in men. 
    When compared to studies conducted on other Latin American populations, our 
results were very similar (Espinosa-Larranaga et al., 2005; Medina-Lezama et al., 2007).  
In a population-based study in Peru, PREVENCION, the most common metabolic 
abnormality in women was low HDL cholesterol (60.9%); whereas, in men it was 
hypertriglyceridemia (52.0%) followed by low HDL cholesterol (32.5%).  Besides 
elevated BMI being very common among men and women in our study, the abnormalities 
found in the PREVENCION study subjects were very similar to those found in our study 
population.  Just as in our study, they too found that abnormal fasting plasma glucose was 
the least common component for men (5.4%) and women (5.0%) (Medina-Lezama et al., 
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2007).  Additionally, in studies conducted in various Central and South American 
countries, Espinosa-Larranaga et al. (2005) concluded that approximately 50% of the 
populations in Argentina, Chile, Paraguay, Peru, and Colombia are overweight and more 
than 15% are obese.  They also found that in Chile, 39.3% of the population had low 
HDL cholesterol; and in Venezuela, men had higher levels of triglycerides (47%) with 
low levels of HDL cholesterol (40%), which is consistent with our findings.   
In this study, dyslipidemia (elevated triglycerides and decreased HDL cholesterol 
levels) is very common.  This pattern of dyslipidemia was also seen in Venezuelan 
subjects with the metabolic syndrome (Florez et al., 2005).  It is possible that dietary 
patterns among Latin Americans contribute to the presence of dyslipidemia.  Martínez-
Ortiz, et al. (2006) positively associated a ‘staple’ dietary pattern, chara terized by an 
increased intake of refined grains (white bread and rice), added sugar, coffee, legumes, 
red meat, and increased use of palm oil for cooking, with lower HDL cholesterol and 
increased risk of myocardial infarction in Costa Rican adults.   
We noticed a pattern among the subjects that demonstrated that the higher the 
BMI, the higher the prevalence of each risk component of the MS as shown in table 4.3.  
Obese subjects had the highest prevalence rates, which were significantly higher t an 
those of overweight subjects, and subjects of normal weight had significantly lower 
prevalence rates than the overweight subjects, with the exception of high glucose and 
hypertension.  The prevalence rates of high glucose and hypertension in normal weight 
and overweight subjects did not vary greatly.  When we compared the mean glucose 
values in subjects classified with normal and overweight BMI, there was no statistically 
significant difference between the groups ( > 0.05).  In an analysis of Mexican-
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American SAHS subjects, (Han et al., 2002) also found that the odds of developing 
metabolic disorders, such as hypertriglyceridemia, low HDL cholesterol, hypertension, 
and type 2 diabetes, increased with a BMI ≥ 30 kg/m2 for men and women.  However, 
they found that the odds of having low HDL cholesterol were greater for overweight as 
opposed to obese women, which is consistent with our findings.   
 In this population, overweight and obesity status, low HDL cholesterol, and high 
triglycerides were very powerful in identifying subjects with the MS. The combinations 
which included glucose were least likely to identify subjects with the metabolic 
syndrome; thus plasma glucose does not seem to aid in identifying high risk compared to 
other variables.  By stratifying this analysis by gender and BMI category, this allowed us 
to distinguish which criteria of the MS is most likely to occur in Hispanics based on 
gender and relative weight.  Hypertriglyceridemia, low HDL cholesterol and 
hypertension are commonly found in those who are insulin-resistant (Espinosa-Larranag  
et al., 2005).  However, we found that this combination of criteria did not capture as 
many subjects as the above mentioned criteria that included BMI, but it did identify 
subjects with normal BMI, which was rare in our population.  The prevalence of 
hypertension in this study was fairly low (11.2% for men and 8.8% for women) which 
differs from studies that show that nearly 30% of the adult Latin American populati n h s 
hypertension (Espinosa-Larranaga et al., 2005).  These combinations which include 
dyslipidemia are especially detrimental because they are associated with type 2 diabetes 
and an increased risk of cardiovascular events (Espinosa-Larranaga et al., 2005).  The 
results of a Pearson partial correlation, controlling for age, revealed that many of the 
metabolic indicators were correlated.  The strongest correlations in our population existed 
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between total cholesterol and LDL cholesterol (r = 0.92), HDL cholesterol and 
triglycerides (r = - 0.49), total cholesterol and triglycerides (r = 0.33), BMI and HDL 
cholesterol (r = - 0.27), BMI and triglycerides (r = 0.26), and SBP and DBP (r = 0.62).  
The correlations found support our results, in that BMI influences other variables, such as 
HDL and triglycerides, and vice versa, as well as the fact that these variables are the most 
prevalent combination of abnormal metabolic components in study subjects. 
 We performed an analysis looking at the differences of metabolic syndrome risk 
factors between subjects that originated from five different Central and South American 
countries. These five sub-groups contained the largest numbers of subjects among all 
countries of origin represented in our study.  The largest Hispanic sub-group in our study 
was from El Salvador (48.8%, n = 508) and the smallest sub-group was from Bolivia 
(5.8%, n = 60).  Subjects from El Salvador had the highest prevalence of MS (30.7%), 
while those from Bolivia had the lowest prevalence (18.3%).  The prevalence of MS was 
also determined for male and female subjects separately.  That analysis showed that 
males from Guatemala had the highest prevalence of MS (46.9%), followed by Honduras 
and Peru, both with 38.5%, then El Salvador with 37%.  There was only one male subject 
from Bolivia with MS (7.1%).  The number of subjects with MS did not differ among 
Honduran, Peruvian, and Guatemalan men.  The prevalence rates for the female subjects
from El Salvador, Honduras, Peru, Guatemala, and Bolivia were 28.2%, 23.5%, 23.7%, 
21.3%, and 21.7%, respectively, which were slightly lower than those of their male 
counterparts.  Our findings show that subjects from Bolivia have lower risks associated 
with the MS.  However, there is not enough evidence to prove any biological or ethnic 
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difference from the other Hispanic sub-groups.  This difference may be due to the small 
sample size of subjects from Bolivia.     
 Because waist circumference measures were not available, we used BMI to 
classify subjects as having one of the criteria for the metabolic syndrome.  Along with the 
NCEP ATP III criteria, we used the overweight/obesity risk factor component used by the 
AACE, which is a BMI of ≥ 25 kg/m2.  The BMI criterion from the AACE clinical 
definition was used because a BMI >25.0 kg/m2 identifies individuals at increased risk 
for insulin resistance and metabolic syndrome (Einhorn et al., 2003).  We felt this BMI 
cutoff was appropriate because of the stature of our subjects.  The average height was 
65.1 ± 2.9 and 60.9 ± 2.7 inches for men and women, respectively.  Had we chosen to use 
a higher BMI, then the MS prevalence may have been underestimated, and other 
metabolic abnormalities would go unnoticed and untreated.  The MS consists of several 
indicators, and the obesity component varies according to the definition used.  Some 
definitions use waist circumference (EGIR, NCEP ATP III, and IDF, while others use 
BMI (WHO and AACE).  Studies have shown that BMI and waist circumference are 
highly correlated, with a correlation coefficient of about 0.91-0.94 in men and 0.88-0.94 
in women (Cheal et al., 2004; Flegal et al., 2009; Ford, Mokdad, & Giles, 2003; Grundy 
et al., 2004).       
 Strengths of this study include its focus on and addition of data to an understudied 
segment of the Hispanic population that is rapidly growing in the U.S and the large 
sample size of study participants.  The use of systematic sampling allows for data to be 
representative of all SCC patients.  Limitations of this study are that wais circumference 
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was not collected at SCC and the patient population used for this study may not be 
representative of Hispanic Americans living in the Washington, D.C. metropolitan are .  
 
Conclusion 
 The prevalence of MS in the U.S. is on the rise. Our results indicate that the 
pattern of chronic disease risk, dyslipidemia and high BMI, increase the likelihood of 
having the MS, which is consistent with studies conducted on Mexican-Americans in the 
San Antonio Heart Study (Han et al., 2002) and other Central and South American 
populations. According to Nath (2005), “Findings from one Hispanic subgroup cannot be 
applicable or extrapolative to other Hispanic subgroups because each subgroup's social 
histories, cultural identities, health behaviors, and genetic compositions are uniqu .” This 
study elucidated whether a difference in MS risk does exist among Hispanic subgroups. 
Our findings showed that there were subtle differences, some statistically significant, 
among each subgroup identified in the study. Results are comparable to those more 












Table 4.1.  Characteristics of the Central and South American study population by 
gender1 
 n Men n Women 
     
Age (years)   338 41.5 ± 13.6 704      42.8 ± 13.2 
       ≤ 34 (%) 114 34 237 34 
     35-44 (%) 96 28 166 24 
     45-54 (%)  66 20 173 25 
     55-64 (%)  46 14 90 13 
       ≥ 65 (%) 16 5 38 5 
Weight (kg.)                                             331 77.3 ± 12.5 701      69.3 ± 14.2 
Height (cm.)                                               323     165.4 ± 7.4 688    154.7 ± 6.9 
BMI (kg/m2)                                             323       28.3 ± 4.1 688      29.0 ± 5.6 
SBP (mmHg)              336     119.7 ± 17.7 703    115.7 ± 18.53 
DBP (mmHg) 336       72.9 ± 12.1 703      71.0 ± 10.93 
TC (mg/dL) 332     191.5 ± 38.9 694    190.5 ± 36.7 
HDL-c (mg/dL) 332       42.9 ± 10.4 694      50.5 ± 12.73 
LDL-c (mg/dL) 320     116.7 ± 33.5 684    113.3 ± 31.3 
TG (mg/dL) 331     163.8 ± 97.9 691    136.4 ± 78.63 
FPG (mg/dL) 329       99.9 ± 31.3 686      93.3 ± 27.93 
1Data are mean ± S.D, unless otherwise specified.   
2Data are percentages (%).  
3Significantly different from men.  
BMI, Body Mass Index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; TC, Total 
Cholesterol; HDL, High Density Lipoprotein-cholesterol; LDL, Low Density Lipoprotein-








Table 4.2.  Prevalence of individual metabolic syndrome components among male 
and female Central and South Americans 
 No. of subjects and % with abnormal MS components 
MS component Men  Women P 
 No. %  No. %  
High BMI (≥ 25 kg/m2) 265 78.4  523 74.9 0.15 
High FPG (110 mg/dl) 42 12.4  59 8.4 0.04 
Low HDL cholesterol† 146 43.2  357 50.7   < 0.01 
High TG (150 mg/dl) 157 46.5  229 32.5   < 0.01 
HBP (130/85 mmHg) 38 11.2  62 8.8 0.21 
†low HDL: male <40 mg/dl, female <50 mg/dl. 
BMI, Body Mass Index; FPG, Fasting Plasma Glucose; HDL, High Density Lipoprotein-











Table 4.3. Number of subjects and prevalence of metabolic syndrome components in 
Central and South Americans by BMI category 
 Number and percent of subjects 
MS Component Normal 
18.5-24.9 









     
High FPG (110 mg/dl) 12 (5%) 30 (7%)   55 (16%) < 0.0001 
Low HDL (< 40 mg/dl)†   43 (19%)  101 (23%) 136 (39%) < 0.0001 
Low HDL (< 50 mg/dl)₤   91 (41%) 249 (57%) 248 (71%) < 0.0001 
High TG (150 mg/dl)   37 (17%) 158 (36%) 173 (49%) < 0.0001 
SBP (≥ 130 mmHg)   34 (15%)   94 (21%) 105 (30%)     0.0001 
DBP (≥ 85 mmHg) 13 (6%) 33 (8%)   63 (18%) < 0.0001 
HTN (130/85 mmHg)   13 (6%)   27 (6%)    54 (15%)   < 0.0001 
Data are n (%).  †low HDL (< 40 mg/dl): males.  ₤low HDL (< 50 mg/dl): females.  
FPG, Fasting Plasma Glucose; HDL, High Density Lipoprotein-cholesterol; TG, Triglycerides; 










Table 4.4.  Identification of the metabolic syndrome using all combinations of any three criteria 
 Number of subjects with metabolic syndrome 
 
Criteria used* Men Women 
  
 Normal  Overweight Obese n P Normal  Overweight Obese n P 
       
 
    
BMI, TG, HDL        0 43 42 85 < 0.0001        0 48 88 136  < 0.0001 
TG, HDL, BP        1 6 6 13    0.35        1 4 14 19     0.003 
TG, HDL, FPG        0 6 8 14    0.01        0 4 17 21  < 0.0001 
HDL, BP, FPG        1 1 3 5    0.27        0 0 3 3     0.07 
BMI, HDL, BP        0 6 6 12    0.14        0 5 20 25  < 0.0001 
BMI, TG, BP        0 11 11 22    0.02        0 1 17 18  < 0.0001 
BMI, TG, FPG          0   11   12   23      0.01        0   8    21   29    < 0.0001 
BMI, FPG, BP        0 2 6 8    0.02        0 0 9 9     0.0004 
BMI, FPG, HDL        0 4 11 15    0.0006        0 8  23 31  < 0.0001 
TG, FPG, BP        0 2 4 6    0.11        0 0 3 3     0.08 
*BMI: men and women, ≥ 25.0 kg/m2; glucose 110 mg/dl; HDL: men < 40 mg/dl, women < 50 mg/dl; triglyceride ≥150 mg/dl; blood pressure 






Table 4.5. Percentage of Central and South Americans meeting metabolic syndrome 




El Salvador Honduras Peru Guatemala Bolivia 
n = 508 n = 107 n = 98 n = 93 n = 60 
      
1  27.4 28.0 28.6 25.8 45.0 
2 21.5 23.4 17.3 33.3   6.7 
3 23.0 19.6 28.6 25.8 15.0 
4   6.5   9.4   1.0   3.2   3.3 
5 
Prevalence  










Total No. of 
















Table 4.6. Percentage of male and female Central and South Americans having MS criteia clustering by country of origin*  






Honduras Peru Guatemala Bolivia  El 
Salvador 
Honduras Peru Guatemala Bolivia 
(n = 160) (n = 39) (n =39) (n = 32) (n = 14)  (n =348) (n = 68) (n = 59) (n = 61) (n = 46) 
            
1 25.0 30.7 23.1 28.1 57.1  28.4 26.5 32.2 24.6 38.8 
2 29.4 17.9 17.9 15.6 21.4  17.8 26.5 16.9 42.6 2.2 
3 26.9 28.2 35.9 43.8 7.1  21.3 14.7 23.7 16.4 17.4 
4 8.0 10.3 2.6 0 0  6.0 8.8 0 4.9 4.3 
























Prev. of MS 37.0 38.5 38.5 46.9 7.1  28.2 23.5 23.7 21.3 21.7 





B) Comparison of metabolic syndrome indicators in two samples of 
Central and South Americans living in the Washington, D.C. area in 





Background: The Central and South American population is growing rapidly in the U.S., 
but little information is known about the health status of this population.  
Objectives:  The purpose of this study was to estimate the prevalence of individual 
components of the metabolic syndrome (MS) as well as the prevalence of MS using data 
from two samples of Central and South Americans utilizing the Spanish Catholic Center 
from 1993 – 1994 and from 2008 – 2009, and to examine how prevalence estimates 
might have changed over time between these groups. 
Design:  This cross-sectional, medical record extraction survey sampled 1,641 adult 
patients of the Spanish Catholic Center (SCC) Medical Clinic in Washington, DC.  A 
questionnaire was used to collect sociodemographic, medical history, anthropometric, 
biochemical, and clinical data.  In this study, the prevalence rates of MS and its 
components were estimated using modified NCEP-ATP III guidelines that included a 
BMI ≥ 25 kg/m2 as a criterion.  
Results:  Among the subjects surveyed in 1993-1994, the MS prevalence was 19.7%. The 
most prevalent MS components were low HDL (40.4% men and 51.3% women), elevated 
triglycerides (40.9% men and 33.1% women), and high BMI ≥ 25 kg/m2 (27.6% men and 
36.6% women).  The overall prevalence of the MS in the subjects surveyed in 2008-2009 
was 28%.  The most common abnormal metabolic indicator was an elevated BMI ≥ 25 
kg/m2 (75.6%).  The results showed that 43.2% of men and 50.7% of women had HDL 
levels lower than normal, while the prevalence of hypertriglyceridemia was 46.5% and 
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32.5% for men and women, respectively.  The prevalence of MS is significantly greater 
for subjects in 2008-2009 compared with subjects in 1993-1994 (p ≤ 0.05).  
Conclusion:  Our results indicate that the pattern of chronic disease risk, dyslipidemia 
and high BMI, increased the likelihood of having the metabolic syndrome. Although this 
distinct pattern was identified in both the 1993-1994 and 2008-2009 study populations, 





Metabolic Syndrome (MS) is a cluster of metabolic abnormalities that occur
together in an individual and are associated with an increased risk of developing 
cardiovascular disease (CVD) and type 2 diabetes mellitus (DM) (Meigs et al., 2003). 
The following abnormalities are considered to be characteristic of the syndrome: glucose 
intolerance, hyperinsulinemia, high plasma triglycerides, decreased high-density 
lipoprotein (HDL) cholesterol, hypertension, central obesity, proinflammatory s ate, and 
prothrombotic state, all of which increase the risk of developing CVD and diabetes (Ford 
& Giles, 2003). MS is closely associated with a generalized metabolic disorder called 
insulin resistance, in which tissue responsiveness to the normal action of insulin is 
impaired (NCEP ATP III, 2002). Overweight/obesity, physical inactivity, genetic factors, 
and poor diet are the underlying causes of the metabolic syndrome (Levesque & 
Lamarche, 2008).  
According to data from the Third National Health and Nutrition Examination 
Survey, 1988 – 1994 (NHANES III), the estimated prevalence of MS among U.S. adults 
was 21.8%, with rates that increased with age (Ford et al., 2002). In a similar study, Ford, 
Giles, & Mokdad (2004), estimated the MS prevalence to be 23.1% among subjects from 
NHANES III; whereas, Ford & Giles (2003) estimated that 23.9% of NHANES III 
participants have the MS. The prevalence of MS among participants from the San 
Antonio Heart and Framingham Offspring Studies in the early to mid 1990’s ranged from 
21.3% and 32.8% using the NCEP-ATP III criteria (Meigs et al., 2003). In later studie , 
the prevalence of MS was estimated to be 26.7% (Ford et al., 2004) and 34.5% (Ford, 
2005) among subjects aged 20 years and older from NHANES 1999 – 2000. These 
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studies suggest that the prevalence of MS increases over time, especially as r tes of 
obesity increase worldwide.  
Much of the known information about chronic diseases in the U.S. has been 
generated by large national studies such as the NHANES. NHANES is conducted to 
ascertain the current health and nutrition status of non-Hispanic whites, non-Hispanic 
blacks, and Hispanic Americans of primarily Mexican, Puerto Rican, and Cuban descet 
living in the U.S. Despite the wealth of information on these established Hispanic 
Americans, generalizations should not be made to other Hispanic subgroups. According 
to Nath (2005), “Findings from one Hispanic subgroup cannot be applicable or 
extrapolative to other Hispanic subgroups because each subgroup's social histores, 
cultural identities, health behaviors, and genetic compositions are unique.” Despite the 
significant awareness of risk factors for CHD in these commonly studied groups of 
Americans, very little is known about the prevalence of metabolic syndrome among 
Central and South Americans. 
  The objectives of this study are to estimate the prevalence of individual risk 
factors for metabolic syndrome as well as the prevalence of metabolic syndrome using 
data from a sample of Central and South Americans utilizing the Spanish Catholic Center
from 1993 – 1994, to estimate the metabolic syndrome prevalence rates of Central and 
South Americans utilizing the SCC in 2008 – 2009, and examine how prevalence 









Subjects and methods 
 
Study populations 
A cross-sectional survey was conducted to assess the prevalence of metabolic 
syndrome and its individual components in a sample of participants attending the Spanish 
Catholic Center (SCC) Medical Clinic in Washington, D.C.  The SCC is a private, non-
profit agency serving Latino’s and the immigrant community.  SCC has locations in 
Washington, D.C. and Montgomery County, Maryland, with a total of four clinics 
(Catholic Charities, 2008).  Data for this study were obtained from the Washington, D.C. 
clinic, which is in a heavily Hispanic neighborhood.  Services are provided based on 
income, and are usually free or low cost.  Our study sample consisted of 1,042 adults 
aged 18 years and older, who reported being from any Central or South American 
country, and who had fasting lipid profile measurements available.  Data were collcted 
by medical record extraction from files at the medical clinic using a questionnaire 
(Appendix A).  On each occasion data were collected, medical records were extracted by 
systematic sampling.  Subjects were identified by an identification number to guarantee 
confidentiality.  Protocols were approved by the SCC and by the Institutional Review 
Board at the University of Maryland, College Park.  
 
Study variables 
A questionnaire was used to obtain sociodemographic information reported by the 
patients.  Sociodemographic variables included date of birth, gender, self-reported 
country of origin, state of residence, education, employment status, and years living in 
the U.S.  Lifestyle variables included current smoking status and alcohol consumption.  
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Medical history information was also collected and used to assess how many subjects had 
been told they had diabetes, hypertension, or heart problems.   
 
Biochemical measures 
Biochemical indices were analyzed by Quest Diagnostics Incorporated in 
Baltimore, Maryland.  Concentrations of fasting plasma lipids and glucose were 
measured using standardized blood analysis techniques.  Blood glucose was analyzed 
using an automated enzymatic method (Caraway & Watts, 1986).  Cholesterol and HDL 
cholesterol were both analyzed enzymatically.  Triglyceride levels were analyzed by 
automated spectrophotometry (Stein, 1986).  LDL cholesterol was mathematically 
derived using the Friedewald formula for subjects with triglyceride levels of 400 mg/dL 
or less (Friedewald et al., 1972).   
 
SCC Coronary Heart Disease Risk Assessment 1993 – 1994 
Data from a cross-sectional study conducted in 1993 – 1994 at the SCC, 
examining coronary heart disease risks in Central and South Americans attending he 
clinical in Washington, D.C. for medical care were also used in this study (Miner & 
Jackson, 1995). The present study parallels this previous study using a similar 
questionnaire and variables and having biochemical indices analyzed by the same 






Metabolic syndrome assessment 
Each subject was assessed for the presence of MS using data collected on fasting 
plasma concentrations of glucose, HDL cholesterol, and triglycerides, blood pressure, 
height, and weight.  The MS was defined by a modified NCEP ATP III definition that 
identified subjects if three or more of the following were present:  (1) BMI ≥ 25 kg/ m2, 
(2) fasting plasma glucose ≥ 110 mg/dl, (3) HDL cholesterol < 40 mg/dl for men and < 
50 mg/dl for women, (4) triglycerides ≥ 150 mg/dl, (5) blood pressure ≥ 130/85 mm Hg 
(NCEP ATP III, 2002).  Data for waist circumference measurements were not available; 
as a result, we substituted a BMI ≥ 25 kg/ m2 for both men and women as an index for 
body weight.  The WHO and AACE have clinical criteria for MS and for the diagnosis of 
Insulin Resistance Syndrome (IRS), respectively, which use BMI instead of waist 
circumference.  WHO uses a cutoff of > 30 kg/ m2 and AACE uses a cutoff of BMI ≥ 25 
kg/ m2 as the body weight component of the syndrome (Scott M Grundy et al., 2004).  In 
this study, the AACE BMI cutoff was used.  BMI was calculated as weight divided by the 
square of height with available measurements and was categorized into four groups:
underweight (< 18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25.0-29.9 
kg/m2), and obese (> 30.0 kg/m2), according to WHO criteria (World Health 




 Descriptive and inferential statistics were used in the analysis. Data were 
presented as means ± standard deviations for continuous variables and as frequencies and 
percentages for categorical variables. We excluded underweight subjects with a BMI < 
 
 61
18.5 kg/m2 (n = 5) and subjects receiving insulin therapy for treatment of diabetes (n = 2).  
From the 607 SCC 1993-1994 study subjects examined, we excluded eight subjects aged 
<18 years. Differences between mean values of MS components based on year f 
attendance at the medical clinic and country of origin were assessed by analysis of 
variance (ANOVA), with a Tukey-Kramer post-hoc test to accommodate groups with 
unequal sample sizes. Chi Square test was used to compare prevalence rates of MS and 
MS components in the two populations and analyses stratified by gender. Student’s t test 
compared independent means between study populations as well as for men and women 
for selected variables. All tests were two-tailed. A significance lev l was set at p ≤ 0.05, 
and analyses were performed using Statistical Analysis System (SAS)Version 9.2; SAS 
Institute Inc., Cary, NC). 
 
Results 
 A total of 1,641 men and women were chosen for our study. A physical exam 
found that subjects were in good general health. Ages ranged from 18 to 87 years. Th  
1993-1994 and 2008-2009 study sample sizes were 599 and 1,042, respectively. 
Anthropometric, biochemical, and clinical characteristics of the two study populations 
stratified by gender are shown in Table 4.7. Among the 1993-1994 subjects, the mean 
age and SD was 37 and 14 years, respectively and 66.1% were women (n = 396). Women 
were significantly older (p ≤ 0.05) and had significantly higher BMI than men (p ≤ 0.05). 
Among the 2008-2009 subjects, the mean age and SD was 42 and 13 years, respectively 
and 67.6% were women (n = 704). Both men and women were similar in age; however, 
women were slightly older.  The majority of subjects in the study were 34 years or 
younger (33.7%; n = 351). Women had a significantly higher BMI than men (p ≤ 0.05).   
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There was heterogeneity by sex among anthropometric measurements and 
metabolic risks within and between the study populations. Metabolic risks were more 
common among men compared with women. Table 4.7 shows that the mean TG value in 
men, as well as mean LDL cholesterol in men and women, exceeded the ATP III cutoff 
criteria for optimal levels. The mean HDL cholesterol value for women in 1993-1994 was 
also lower than the ATP III cutoff criterion and lower than the mean for women from 
2008-2009.  Overall, when the two populations were compared as a whole, the 2008-
2009 subjects had significantly higher BMI, lower fasting glucose, and lower systolic and 
diastolic blood pressures (p ≤ 0.05). 
 When comparing men from the previous and present studies, many of the 
characteristics were similar. Men from the 1993-1994 study had significantly higher 
systolic and diastolic blood pressures (p ≤ 0.05); whereas men from the present study 
were significantly heavier, had a higher BMI, and were older (p ≤ 0.05). When the 
women from each study were compared, a number of differences were identified betw en 
them. Besides being significantly heavier, taller, and older (p ≤ 0.05), the women from 
the 2008-2009 study had lower mean metabolic risk values, some being significantly 
lower, such as fasting glucose, total cholesterol, and blood pressure.   
Country of origin was subject reported. Nearly 50% of each study population 
reported being from El Salvador. Results indicate that the majority of subjects (63%) 
from 1993-1994 resided in Washington, D.C., whereas the majority of subjects (57%) 
from 2008-2009 resided in Maryland at the time of the study, and were employed with a 
median income of approximately $7,800 to $13,000 per year. Most of the subjects were 
either married (40% vs. 45%) or single (46% vs. 42%) in the 1993-1994 and 2008-2009 
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studies, respectively. In the 2008-2009 study, of those who had dependents, the average 
number was 2.6 and 2.3 for men and women, respectively. A total of 69% of subjects had 
primary or secondary education, while only 23% spoke English fluently. Only about 100 
(11%) subjects had medical insurance. The average number of years that subjectshad 
been living in the U.S. was 8.8 years. In the 1993-1994 study, nearly all (96%) subjects 
obtained primary or secondary education, only 2% of subjects had medical insurance, and 
only 8% spoke fluent English. 
Table 4.8 shows the prevalence of individual MS components and the MS among 
male and female Central and South American subjects from the 1993-1994 and 2008-
2009 study samples. The prevalence of having low HDL was very high among all 
subjects. The most prevalent MS indicators among men in 1993-1994 were low HDL 
(40.4%) and high TG (40.9%), while low HDL (51.3%) and high BMI (36.6%) were 
most prevalent for women. Women had a significantly higher prevalence of low HDL 
compared to men in both study samples (51.3% vs. 40.4% in 1993-1994 and 50.7% vs. 
43.2% in 2008-2009) (p ≤ 0.05). For those men and women in the 2008-2009 study, the 
most common abnormal indicators of the MS was a high BMI (78.4% of men and 74.3% 
of women), as used in the AACE definition (Scott M Grundy et al., 2004), low HDL, and 
high TG. The overall prevalence of hypertension was 9.6% among men and women in 
2008-2009. Of the 23.4% of subjects who had a SBP at or above 130 mmHg, 36.1% were 
men and 63.9% were women. As for an elevated DBP, only 11% of subjects met or 
exceeded this criterion. On the contrary, subjects in 1993-1994 had higher prevalence 
rates of elevated SBP and DBP. The difference in prevalence rates of hypertension was 
statistically significant for both men (20.2% vs. 11.2%) and women (18.7% vs. 8.8%) (p 
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≤ 0.05). The prevalence of MS is significantly greater for subjects in 2008-2009 
compared with subjects in 1993-1994 (p ≤ 0.05).  
The prevalence of MS component clustering among men and women from the 
1993-1994 study is presented in Table 4.9. Clustering of abnormal MS components was 
more prevalent among men at each level of clustering (two through five components) 
when compared to women, except for the clustering of four components. Overall, 152 
men had one or more MS components, with the majority of those men having only one 
component (31.5%). Women were more likely than men to have only one component 
(32.3%). However, men had a higher prevalence of clustering of 3 components, 
indicating having the MS, compared to women (14.8% vs. 13.4%). Based on the number 
of subjects with three, four, or five MS components, the prevalence of MS for men was 
19.7% (n = 40) and the prevalence for women was also 19.7% (n = 78).  
In the population studied in 2008-2009, 29.3% of men had one abnormal 
component, 26.0% of men had two abnormal components, 26.9%, 5.9%, and 1.2% of 
men had three, four, or all five abnormal components of the MS. When compared to men, 
these percentages were generally lower for women, with values of 29.7, 19.7, 19.9, 4.7, 
and 0.4%, respectively. The total prevalence of MS in this study population was 27.9%. 
The prevalence for men was 34.0% (n = 115) and the prevalence for women was 25% (n 
= 176).  
In both the 1993-1994 and 2008-2009 study populations, the most frequently 
reported country of origin was El Salvador. There were a total of 804 Salvadorian 
subjects in the study, 296 were from the 1993-1994 study and 508 were from the 2008-
2009 study. The difference in MS risks over time was determined in this subset of the 
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study subjects. Table 4.10 shows the anthropometric and metabolic characteristics of 
subjects from El Salvador from the 1993-1994 and 2008-2009 studies. Subjects from 
2008-2009 were significantly heavier than their counterparts from 1993-1994 (P ≤ 0.05). 
Mean BMI for subjects from 1993-1994 was 28.1 ± 12.5, while subjects from 2008-2009 
had a mean BMI of 29.3 ± 5.2, this difference is statistically significant (P ≤ 0.05). Many 
of the values of biochemical variables measured in the study were similar among both 
populations. The mean DBP of subjects from 2008-2009 was significantly lower (72.0 
±12.1 vs. 80.2 ± 11.1) when compared to the other Salvadoran subjects (P ≤ 0.05). This 
was the only statistically significant difference between biochemical variables among the 
two study populations. Most of the values were greater in the 1993-1994 study 
population, although not significant.   
An elevated BMI of ≥ 25 kg/m2 was more prevalent among the more recent study 
subjects. There was a statistically significant difference between the prevalence of 
elevated BMI of the two study populations (χ2, P ≤ 0.05). This statistical difference was 
seen at a BMI of ≥ 25 kg/m2 and ≥ 30 kg/m2. Prevalence rates for hypertriglyceridemia, 
elevated SBP, and high TC were higher among subjects from 2008-2009, however these 
differences were not statistically significant.  
 
Discussion 
The overall prevalence of MS in the present study was 29.7%. Male subjects had 
a MS prevalence of 34.0%, while the prevalence for female subjects was 25%.  In the 
previous study in 1993-1994, the overall MS prevalence was 19.7%, and the prevalence 
of MS in both men and women was also 19.7%. These estimates indicate an increase in 
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the prevalence of MS over time, which was also demonstrated in a study by Ford etal. 
(2004) when determining whether the prevalence of MS had changed from NHANES III 
(23.1%) to NHANES 1999 – 2000 (26.7%). It was noted that the increase in the 
prevalence of MS was mainly due to increases in waist circumference and 
hypertriglyceridemia. An examination of the prevalence of MS and individual risk factors 
for MS in participants from NHANES 2003 – 2006 found that the overall prevalence was 
34% (Ervin, 2009), much higher than that found in the NHANES 1999 – 2000 and in our 
estimate from 1993 – 1994.  
There are several statistical differences in mean biochemical measures between 
men and women from the two studies. The majority of those differences are seen among 
women. We expected the mean biochemical values to increase over time, especially with 
worsening obesity; however, that did not occur for all variables. Values for women in the 
2008 – 2009 population that were significantly different from the women in the 1993 – 
1994 population were lower (SBP, DBP, TC, and FPG), thus indicating that certain risks 
have decreased. The differences between mean values of men in the two studies were not 
as great. SBP and DBP were the only variables that were significantly greater in the 1993 
– 1994 population, all else were similar. Weight, BMI and age were greater in the 2008 –
2009 study participants when compared to participants from the previous study. The 
prevalence of MS was also greater in this present study sample, which is consistent w th 
studies that demonstrated that the MS prevalence increased with BMI (Lorenzo et al., 
2006) and age (Ervin, 2009; Medina-Lezama et al., 2007).  
In the 1993 – 1994 cohort of Central and South Americans, the most prevalent 
metabolic abnormalities were low HDL cholesterol (40.4% men and 51.3% women), 
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hypertriglyceridemia (40.9% men and 33.1% women), and elevated BMI (27.6% men 
and 36.6% women). The prevalence of having a BMI ≥ 25 kg/m2 and low HDL < 50 
mg/dL and < 40 mg/dL for women and men, respectively, was significantly greater in 
women compared to men. The 2008 – 2009 cohort of Central and South Americans 
experienced a very similar pattern of prevalent metabolic abnormalities. Th  most 
prevalent abnormalities were elevated BMI (78.4% men and 74.9% women), 
hypertriglyceridemia (46.5% men and 32.5% women), and low HDL cholesterol (43.2% 
men and 50.7% women). High FPG levels were not as frequent as one might expect in a 
population in which 78% of its subjects had a BMI at or above 25 kg/m2. The MS 
prevalence was significantly greater in the present population than in the previous 
population (p ≤ 0.05), mainly due to the significant increases in the number of subjects 
meeting and exceeding the BMI criterion of ≥ 25 kg/m2. The MS has increased by a 
substantial amount between 1994 and 2009, especially in men (19.7% vs. 34.0%). 
  When compared to studies conducted on other Hispanic American populations, 
our results were very similar (Espinosa-Larranaga et al., 2005; Medina-Lezama et al., 
2007). In a population-based study in Peru, PREVENCION, the most common metabolic 
abnormality in women was low HDL cholesterol (60.9%); whereas, in men it was 
hypertriglyceridemia (52.0%) followed by low HDL cholesterol (32.5%). Besides 
elevated BMI being very common among men and women in our study, the abnormalities 
found in the PREVENCION study subjects were very similar to those found in the 1993 
– 1994 and 2008 – 2009 study populations. Just as in our study, they too found that 
abnormal fasting plasma glucose was the least common component for men (5.4%) and 
women (5.0%) (Medina-Lezama et al., 2007). Additionally, in studies conducted in 
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various Central and South American countries, Espinosa-Larranaga et al., (2005) 
concluded that approximately 50% of the populations in Argentina, Chile, Paraguay, 
Peru, and Colombia are overweight and more than 15% are obese. They also found that 
in Chile, 39.3% of the population had low HDL cholesterol; and in Venezuela, men had 
higher levels of triglycerides (47%) with low levels of HDL cholesterol (40%), which is 
consistent with our findings.  
Mexican-Americans from San Antonio, TX have also been identified as having 
prevalent dyslipidemia, with hypertriglyceridemia (48.9% men and 36.8% women), low 
HDL cholesterol (53.6% men and 60.4% women), and large waist circumference (31.2% 
men and 56.4% women), but this sample also had a much higher prevalence of 
hypertension (44.1% men and 36.9% women) than our Central and South American 
subjects (Meigs et al., 2003). Cheal et al., (2004) determined that “being overweight, in 
combination with high plasma triglycerides and/or low HDL cholesterol, was a powerful 
predictor of having the metabolic syndrome.”  
In this study, dyslipidemia (elevated triglycerides and decreased HDL cholesterol 
levels) is very common. This pattern of dyslipidemia was also seen in Venezuelan 
subjects with the metabolic syndrome (Florez et al., 2005).  It is possible that dietary 
patterns among Latin Americans contribute to the presence of dyslipidemia.  Martínez-
Ortiz, et al. (2006) positively associated a ‘staple’ dietary pattern, chara terized by an 
increased intake of refined grains (white bread and rice), added sugar, coffee, legumes, 
red meat, and increased use of palm oil for cooking, with lower HDL cholesterol and 
increased risk of myocardial infarction in Costa Rican adults.  
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As can be seen from Table 4.9, the percentages of subjects with 1 or more MS 
components are not consistently greater in one sex or the other. Women have higher 
prevalence estimates of one (32.3% vs. 31.5%) and four (5.8% vs. 3.4%) abnormal 
components compared to men, respectively, which have higher prevalence estimates of 
two, three, and five components. The prevalence estimates for clustering of MS 
components found in the 2008 – 2009 study population were similar, in that women had a 
higher prevalence of one abnormal component compared to men, but men had higher 
prevalence estimates for two through five components. Much like the women in the 
2008-2009 study, the number of women with the MS is greater than that of men (78 vs. 
40). However, the prevalence of MS is the same for both men and women, which 
indicates very similar risks.  
A similar study by Medina-Lezama et al. (2007) found that Peruvian women had 
higher prevalence estimates for one through five components of the MS. In that study, 
31.8% of women had the MS with 3, 4, or all 5 components as opposed to 17.8% of men. 
In a another study, Cheal et al. (2004) determined that the men had higher prevalence 
estimates of one, two, four, and all five components of the MS. Along with the previous 
study, this 2004 study also identified women as having a higher prevalence of the MS.  
We performed an analysis looking at the differences of metabolic syndrome risk 
factors between subjects that originated from the largest Hispanic sub-gro p in our study. 
In both the 1993 – 1994 and 2008 – 2009 studies, El Salvador was the most frequently 
reported county of origin, 49.4% and 48.8%, respectively, of all countries reported. As 
shown in Table 4.10, no real difference in MS characteristics exists between the 1993-
1994 and 2008-2009 sample of Salvadorans. Differences that do exist follow the same 
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pattern as what was seen when the entire study populations were compared, which are an 
increase in the prevalence of high BMI and a decrease in the prevalence of hyp rtension 
among subjects from 2008 – 2009. The results from the anthropometric characteristics, 
biochemical variables, and MS characteristics of Salvadorian subjects are onsistent with 
the other Central and South American subjects used in our study as a whole, thus 
indicating similar metabolic risks. However, in an examination comparing El Salvador to 
other countries individually, differences in metabolic risks may exist. 
Strengths of this study include its focus on and addition of data to an understudied 
segment of the Hispanic population that is rapidly growing in the U.S and the large 
sample size of study participants.  The use of systematic sampling allows for data to be 
representative of all SCC patients.  Comparing data from two different time periods 
allowed for comparison of trends in MS prevalence over time.  Limitations of this study 
are that waist circumference was not collected at SCC and the patient population sed for 
this study may not be representative of Hispanic Americans living in the Washington, 
D.C. metropolitan area.   
 
Conclusion 
The prevalence of MS has increased over time. When the two study populations 
were compared, it was determined that the prevalence of MS was higher in the present
study, with a more noticeable increase among men. Subjects from 1993 – 1994 and 2008 
– 2009 had the same prevalent metabolic abnormalities. Our study, as well as other 
studies of Central and/or South Americans, suggests that “being overweight, in 
combination with high plasma triglycerides and/or low HDL cholesterol, was a powerful 
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predictor of having the metabolic syndrome” (Cheal et al., (2004). It is possible that 
dietary patterns among Hispanic Americans contribute to the presence of dyslipidemia. 
For these subjects with dyslipidemia and elevated BMI, medical treatment, drug therapy, 
and dietary changes could help lower the risk of MS and subsequent CVD and DM.  
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Table 4.7.  Characteristics of the Central and South American study population by gender in 1993 – 1994 and 2008 – 20091 
  1993 - 1994  2008 - 2009 
  n Men n Women  n Men n Women 
           
Age (years)    203 35.1 ± 19.4 396 38.9 ± 14.2  338 41.5 ± 13.63  704 42.8 ± 13.22  
       ≤ 34 (%)  119 58.6 180 45.5  114 33.7 237 33.6 
     35-44 (%)   40 19.7 95 24.0  96 28.4 166 23.6 
     45-54 (%)  23 11.3 59 14.9  66 19.5 173 24.6 
     55-64 (%)  14 6.9 40 10.1  46 13.6 90 12.8 
       ≥ 65 (%)  7 3.5 22 5.6  16 4.7 38 5.4 
Weight (kg.)  163 71.2 ± 11.4 350 64.6 ± 12.8  331 77.3 ± 12.53 701 69.3 ± 14.22 
Height (cm.)  91 164.8 ± 8.2 198 153.0 ± 7.3  323 165.4 ± 7.4 688 154.7 ± 6.92 
BMI (kg/m2)  91 26.1 ± 3.8 198 28.4 ± 5.2  323 28.3 ± 4.13 688 29.0 ± 5.6 
SBP (mmHg)  185 123.3 ± 19.4 369 119.8 ± 21.2  336 119.7 ± 17.73 703 115.7 ± 18.52 
DBP (mmHg)  185 82.2 ± 11.1 369 79.2 ± 11.2  336 72.9 ± 12.13 703 71.0 ± 10.92 
TC (mg/dL)  203 192.7 ± 44.7 389 195.7 ± 48.5  332 191.5 ± 38.9 694 190.5 ± 36.72 
HDL-c (mg/dL)  201 43.8 ± 11.6 387 49.9 ± 12.4  332 42.9 ± 10.4 694 50.5 ± 12.7 
LDL-c (mg/dL)  192 116.5 ± 34.6 379 116.9 ± 31.8  320 116.7 ± 33.5 684 113.3 ± 31.3 
FPG (mg/dL)  202 102.0 ± 41.9 389 99.2 ± 46.2  329 99.9 ± 31.3 686 93.3 ± 27.92 
TG (mg/dL)  203 167.6 ± 132.3 389 136.5 ± 83.2  331   163.8 ± 97.9 691    136.4 ± 78.6 
1 Data are mean ± S.D, unless otherwise specified.  2 Significantly different from women in the 1993-1994 population.  3 Significantly different 
from men in the 1993-1994 population. 
BMI, Body Mass Index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; TC, Total Cholesterol; HDL, High Density Lipoprotein-
cholesterol; LDL, Low Density Lipoprotein-cholesterol; FPG, Fasting Plasma Glucose; TG, Triglycerides 
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Table 4.8.  Prevalence of individual metabolic syndrome components and the metabolic syndrome among Central and South 
American men and women from 1993 – 1994 and 2008 – 2009 
 No. and % with abnormal MS components 
1993-1994 (n=599)      
Component Men (n = 203)  Women (n = 396) 
 n %  n % 
High BMI* 56 27.6  145 36.62 
Low HDL† 82 40.4  203 51.32 
Hypertension 41 20.2  74 18.7 
High FPG 31 15.3  44 11.1 
High TG 83 40.9  131 33.12 
MS prevalence 40 19.7  78 19.7 
      
      
2008-2009 (n=1042)      
Component Men (n = 338)  Women (n = 704) 
 n %  n % 
High BMI 265 78.41  523 74.31 
Low HDL† 146 43.2  357 50.72 
Hypertension 38 11.21  62 8.81 
High FPG 42 12.4  59 8.42 
High TG 157 46.5  229 32.52 
MS prevalence 115 34.01  176 25.012 
Data are %.  * BMI ≥ 25 kg/m2; HDL, High Density Lipoprotein-cholesterol; FPG, Fasting Plasma Glucose; †low HDL: male <40 
mg/dl, female <50 mg/dl; TG, Triglycerides; 1 Significantly different from 1993-1994 population; 2 Significantly different from men
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Table 4.9.  Prevalence of MS clustering among Central and South American men 
and women from 1993-1994 and 2008-2009 
1993-1994 Men Women 
No. of components n = 203 n = 396 
   
1 31.5 32.3 
2 23.6 19.9 
3 14.8 13.4 
4 3.4 5.8 
5 1.5 0.5 
Total No. of subjects w/ MS 40 78 
Prevalence of MS 19.7 19.7 
   
2008-2009 Men Women 
No. of components n = 338 n = 704 
   
1 29.3 29.7 
2 26.0 19.7 
3 26.9 19.9 
4 5.9 4.7 
5 1.2 0.4 
Total No. of subjects w/ MS 115 176 
Prevalence of MS 34.0 25.0 
















Table 4.10.  Anthropometric and metabolic characteristics of subjects from El 
Salvador from 1993 – 1994 and 2008 – 20091  
  1993 – 1994  2008 – 2009 
  n  296  508 
Anthropometric characteristics      
  Weight (kg.)  68.3 ± 12.5  73.2 ± 14.22 
  Height (cm.)  157.6 ± 9.6  157.7 ± 78.0 
  BMI (kg/m2)                                             28.1 ± 4.8  29.3 ± 5.22
     
Biochemical variables     
  Fasting Plasma Glucose (mg/dL)  99.0 ± 35.6  96.6 ± 32.0 
  Triglyceride (mg/dL)  153.5 ± 115.1  150.9 ± 87.4 
  Systolic Blood Pressure (mmHg)  120.0 ± 19.0  118.2 ± 19.1 
  Diastolic Blood Pressure (mmHg)  80.2 ± 11.1  72.0 ±12.12 
  High Density Lipoprotein (mg/dL)  45.7 ± 11.6  46.2 ± 11.4 
  Low Density Lipoprotein (mg/dL)  112.6 ± 30.8  114.4 ± 30.5 
  Total Cholesterol (mg/dL)  188.5 ± 38.8  190.3 ± 37.0 
     
Metabolic syndrome characteristics     
  High BMI (% population)  34.5  79.52 
  High FPG (% population)  12.8  9.8 
  High TG (% population)  34.8  38.0 
  Hypertension (% population)  18.2  11.22 
  Low HDL (% population)3  65.9  65.6 
1 Means ± SD, unless otherwise specified. 
2 Significantly different from the 1993 – 1994 population, P ≤ 0.05 (Student’s t test for 
continuous variables and chi-square test for categorical variables). 
3 HDL < 50 mg/dL for the entire population. 
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Chapter 5:  Summary and Implications 
Summary 
 The purpose of this study was to provide information on MS risk among a sample 
of Central and South Americans attending a large Catholic medical clinic and to 
determine if this population is at equal or greater risk for metabolic abnormalities than 
more established Hispanic Americans (Mexican Americans) living in the U.S. This 
thesis examined: (1) the prevalence of abnormal MS indicators (FPG, TG, HDL, HBP, 
BMI), (2) the differences in the prevalence of MS among various Hispanic sub-gro ps, 
(3) the difference in the prevalence of abnormal MS indicators based on BMI 
categories, and (4) how the prevalence of MS and abnormal MS indicators in a 2008-
2009 study population compare to previous subject data obtained in 1993-1994 from 
the same medical clinic.  
 The major findings suggest that among the 2008-2009 sample of Central and 
South Americans, the prevalence of MS components increases steadily as relative 
weight increases; thus increasing the likelihood of developing other abnormal risk 
factors. High triglyceride and low HDL cholesterol levels, in addition to elevated BMI 
≥ 25 kg/m2, were the most common metabolic abnormalities in this population for both 
men and women. This combination of dyslipidemia and elevated BMI puts subjects at 
an increased risk for insulin resistance. High blood pressure was not prevalent, but 
when in combination with dyslipidemia and high BMI, it may further increase the risk 
for inflammation, insulin resistance and type 2 DM.  The overall prevalence of MS was 
very similar among subjects from El Salvador, Honduras, Peru, and Guatemala, with 
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prevalence rates of 30.7%, 29.0%, 29.6%, and 30.1%, respectively.  Subjects from 
Bolivia had a substantially lower MS prevalence of 18.3%. 
When the two study populations were compared, it was determined that the 
prevalence of MS was indeed higher in the 2008-2009 study, with a more noticeable 
increase among men (19.7% in 1993-1994 vs. 34.0% in 2008-2009) (P ≤ 0.05). Subjects 
from 1993-1994 and 2008-2009 had the same prevalent metabolic abnormalities, and in 
some instances, the prevalence estimates of individual MS components were greater in 
the 1993-1994 population.  Overall, the 2008-2009 subjects had significantly higher BMI, 
lower fasting glucose, and lower systolic and diastolic blood pressure (p ≤ 0.05).   
 
Implications 
With this information, drug therapy, public policy, and dietary changes could help lower 
the risk of MS and subsequent CVD and type 2 DM in these Central and South American 
groups.  Although a reduction in blood pressure and glucose levels are recommended 
goals for managing MS (Grundy et al., 2004), this population has a lower prevalence of 
these risk factors; therefore, an emphasis should be placed on reducing the prevalence of 
dyslipidemia and relative weight reduction.  
A target of therapy would be to reduce atherogenic dyslipidemia, which causes 
CVD.  Statins, which are commonly recognized for their cholesterol-lowering properties, 
can “reduce risk for CVD events in patients with metabolic syndrome” (Grundy et al.,
2004).  Fibrates also play a role in reducing atherogenic dyslipidemia by reducing plasma 
TG levels and moderately increasing HDL cholesterol concentrations (Levesque & 
Lamarche, 2008).  Clinical studies have shown that combined statin-fibrate therapy 
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demonstrates improvements in abnormal lipoprotein patterning and CVD risk status 
(Grundy et al., 2004; Levesque & Lamarche, 2008).  The Central and South American 
subjects studied would greatly benefit from such therapies. 
 This thesis was intended to raise awareness of the prevalence of MS in an 
understudied group of Hispanics, Central and South Americans.  The subjects utilizing 
the medical clinic used in the study are, for the most part, immigrants, yet the suggested 
therapies to improve CVD risks might be unattainable for most of these immigrants.  
With this new information, policy-makers and health care professionals can find a way to 
provide free or low-cost prescription drugs that would improve the CVD and type 2 DM 
risk status. 
 Finally, dietary changes are very important in lowering obesity and preventing 
cardiovascular events.  Reducing caloric intake and increasing physical act vity will be 
helpful in reducing CVD risks.  Providing nutrition education is crucial to understanding 
the relationship of diet and disease.  Individuals with MS should adhere to basic dietary 
principles, such as ‘low intakes of saturated fats, trans fats, and cholesterol, reduced 
consumption of simple sugars, and increased intakes of fruits, vegetables, and whole 















Appendix A: Metabolic Syndrome Risk Questionnaire 
Spanish Catholic Center 
Variable                          Input Variable                                 Columns 
CARD 1 
1. Identification number                       _______________ IDNO       1-4 
2. Appointment date at SCC                _______________ DATE      5-10 
3. Patient’s state of residence           _______________   ADDRESS             11-12 
WDC=1; MD=2; VA=3 
 
4. Patient’s country of origin           _______________  ORIGIN   13-14 
(El Salvador=1; Honduras=2; Peru=3; 
Argentina=4; Guatemala=5; Colombia=6; 
Nicaragua=7; Bolivia=8; Puerto Rico=10; 
Brazil=11; Cuba=12; Dom. Republic =13; 
Other=14; Ecuador=15; Paraguay=16; Mexico=17; 
Panama=18; Chile=19; Venezuela=20 
 
5. Date of birth  (mm/dd/yy)           ________________ AGE               15-20 
6. Gender of patient (M=1, F=2)          ________________ SEX       21 
7. Marital status (M=1; S=2; D=3; W=4)  _____________ MARITAL      22 
8. Level of education completed          ________________ EDUC       23 
(pri=1; high=2; coll=3; tech=4;  
None=5; missing=9) 
 
9. Do you work? (Yes=1; No=2)          ________________ WORK      24 
10. Hours per week (miss=999)           ________________ HOURS   25-27 
11. Household salary (miss=999999)      ________________ SALARY          28-33 
12. Do you speak English? (Y=1; N=2;  ________________ ENGLISH      34 
Miss=9) 
 
13. Do you have health insurance?         ________________ INSURED      35 




14. Number of dependents                     _________________ NODEPEND     36-38 
Medical History  (Patient Reported) 
15. Years living in the U.S.                    _________________ YEARSUS   39-40 
 
16. Do you have Hypertension?           _________________ HBP       41 
(Y=1; N=2; miss=9) 
 
17. Do you have Diabetes?           _________________ DIABETES      42 
18. Do you have Tuberculosis?           _________________ TB       43 
19. Do you have Epilepsy?           _________________ EPIL       44 
20. Do you have Arthritis?            _________________ ARTH       45 
21. Do you have Heart trouble?            _________________ HEART      46 
22. Do you have Allergies?           _________________ ALLGY                47 
23. Do you smoke?            _________________ SMOKE      48 
24. Do you drink alcohol?            _________________ DRINK      49 
25. Do you drink coffee?            _________________ COFF       50 
Hematology and Biochemistry Results 
26. Hematocrit (%)            _________________ HCT .1  51-53 
27. Hemoglobin (g/dl)            _________________ HGB .1  54-56 
28. Red Blood Cell (mil/mm3)            _________________ RBC .2  57-59 
29. MCV (cu microns)            _________________ MCV    60-62 
30. MCH (pg/cell)             _________________ MCH .1   63-65 
31. MCHC (%)             _________________ MCHC .1   66-68 
32. WBC (thou/mm3)             _________________ WBC .1   69-71 
33. Lymphocyte (%)             _________________ LYMPH .1   72-74 
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34. Neutrophil (%)             _________________ NEUTRO .1   75-77 
 
CARD 2 
35. Monocyte (%)             _________________ MONO .1      1-2 
36. Eosinophil (%)            _________________  EOSIN .1      3-5 
37. Basophil (%)              _________________ BASO .1      6-7 
38. Platelet (thou/mm3)             _________________ PLATE     8-10 
39. What is the Urine color?           _________________ COLOR      11 
(yell=1; straw=2; amber=3) 
 
40. What is the Urine appearance?          ________________ APPEAR      12 
(clear=1; hazy=2) 
 
41. What is the Urine pH?           _________________ PH .1    13-15 
42. Specific gravity            _________________ SG .3    16-19 
43. Is there glucose in the urine?           _________________ UGLC                   20 
(pos=1; neg=2) 
 
44. Is there protein in the urine?           _________________ UPROT      21 
45. Are there ketones in the urine?         _________________ UKETONE      22 
46. Is there blood in the urine?            _________________ UBLOOD      23 
47. Bilirubin             _________________ BILIRUBN      24 
48. Urobilinogen             _________________ UROBIL      25 
49. Leukocyte esterase            _________________ LEUKEST      26 
50. Nitrite              _________________ NITRITE      27 
51. WBC in urine             _________________ UWBC      28 
52. RBC in urine             _________________ URBC       29 
53. Urinary Epithelial cells           _________________ UEPITH      30 
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54. Mucus in urine            _________________ UMUCUS      31 
55. Urinary bacteria            _________________ UBACT      32 
56. Urinary crystals            _________________ UCRYST      33 
57. Urinary casts             _________________ UCASTS      34 
58. Virology (RPR-qual)             _________________ VIRQUAL      35 
59. Virology (RPR-quan)            _________________ VIRQUAN      36 
60. Blood glucose (mg/dl)           _________________  GLUC   37-39 
61. Blood urea nitrogen (mg/dl)           _________________ BUN              40-41 
62. Creatinine (mg/dl)            _________________ CREAT .2  42-44 
63. Sodium (meq/l)            _________________    NA    45-47 
64. Potassium (meq/l)            _________________ K .1    48-49 
65. Chloride (meq/l)            _________________ CL    50-52 
66. Carbon Dioxide (meq/l)            _________________ CO2    53-54 
67. Uric acid (mg/dl)            _________________ URIC    55-56 
68. Total Protein (g/dl)            _________________ TOTPROT .1   57-58 
69. Albumin (g/dl)             _________________ ALBMN .1   59-60 
70. Globulin (g/dl)             _________________ GLBLN .1   61-62 
71. Albumin/globulin ration            _________________ AGRATIO .1   63-64 
72. Calcium (mg/dl)            _________________ BCALC .1   65-67 
73. Phosphorus (mg/dl)            _________________ BPHOS   68-69 
74. Cholesterol (mg/dl)            _________________ BCHOL   70-72 




76. LDL cholesterol (mg/dl)           _________________ LDL    1-3 
77. Chol/HDL ratio             _________________ CHORATIO .1   4-5 
78. Triglycerides (mg/dl)             _________________ TG    6-8 
79. Alkaline Phosphatase (U/l)           _________________ ALKPHOS   9-11 
80. SGOT (U/l)             _________________ SGOT    12-13 
81. SGPT (U/l)             _________________ SGPT    14-15 
82. Lactic Dehydrogenase (U/l)           _________________ LD    16-18 
83. Total bilirubin             ________________ TOTBILI .1   19-20 
84. Ferritin (ng/ml)            _________________ FERR    21-23 
85. Gamma Glutamyl Tranferase (U/l)   _________________ GGT    24-26 
86. Weight (lbs.)             _________________ WT    27-29 
87. Height (in.)             _________________ HT    30-31 
88. Systolic BP (mm Hg)            _________________ SBP    32-34 
89. Diastolic BP (mm Hg)           _________________ DBP    35-37 
90. Waist circumference (in.)           _________________ WC    38-40 
91. What was the reason for the visit?    _________________ VISIT      41 
Physical exam/checkup/F/U=1; acute illness=2; 
Chronic pain = 3 
 













Appendix B:  Subject reported country of origin 
Country Number of subjects % of subjects 
   
El Salvador 508 48.8 
Honduras 107 10.3 
Peru 98 9.4 
Argentina 11 1.0 
Guatemala 93 8.9 
Colombia 45 4.3 
Nicaragua 29 2.8 
Bolivia 60 5.8 
Brazil 15 1.4 
Dominican Republic 25 2.4 
Ecuador 18 1.7 
Chile 4 0.4 
Venezuela 3 0.3 
Other* 26 2.5 
Total  1042 100 % 
*Subjects that reported being from countries such as Costa Rica, Paraguay, Uruguay, Puerto 
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